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Poor water-solubility is a common characteristic of drug candidates in 
pharmaceutical development pipelines today.   Various processes have been developed to 
increase the solubility, dissolution rate and bioavailability of these active ingredients 
belonging to BCSII and IV classifications.  Over the last decade, nano-crystal delivery 
forms and amorphous solid dispersions have become well established in commercially 
available products and industry literature.  Chapter 1 is a comparative analysis of these two 
methodologies primarily for orally delivered medicaments.  The thermodynamic and 
kinetic theories relative to these technologies are presented along with a survey of 
commercial relevant scientific literature.  Marketed products from both technologies are 
presented, but there appears to be more amorphous dispersion products on the U.S. market 
today and current development trends are showing an industry preference for amorphous 
solid dispersions. 
Many pharmaceutical polymers have been investigated as the primary component 
in amorphous solid dispersions for their ability to increase the apparent water solubility of 
poorly water-soluble drugs.  Polyvinyl alcohol (PVAL) has not been investigated as a 
concentration enhancing polymer owing to its high melting point/high viscosity and poor 
organic solubility.  Due to the unique attributes of the KinetiSol® Dispersing (KSD) 
 viii 
technology, PVAL has been enabled for this application and Chapter 2 contains an initial 
investigation into various grades for improvement of the solubility and bioavailability of 
the poorly water-soluble model drug, itraconazole (ITZ).  Polymer grades were chosen with 
variation in molecular weight and degree of hydroxylation to determine the effects on 
performance.  Differential scanning calorimetry, powder x-ray diffraction, polarized light 
microscopy, size exclusion chromatography and dissolution testing were used to 
characterize the amorphous dispersions.  An in vivo pharmacokinetic study in rats was also 
conducted to compare the selected formulation to current market formulations of ITZ. 
Chapter 3 continues the investigation into the use of PVAL as a concentration 
enhancing polymer for amorphous solid dispersion.  The previous chapter revealed that the 
88% hydrolyzed grade was optimal for ITZ compositions with regard to solid-state 
properties, non-sink dissolution performance and bioavailability enhancement.  This 
chapter explores the influence of molecular weight for the 88% hydrolyzed grade in the 
range of 4 to 8 mPa·s with the top performing grade from both chapters emerging as PVAL 
4-88.  Amorphous dispersions at 10, 20, 30, 40 and 50% ITZ drug loads in PVAL 4-88 
were compared by dissolution performance.  Analytical tools of diffusion-ordered 
spectroscopy and Fourier transform infrared spectroscopy were employed to understand 
the interaction between drug and polymer.  Finally, results from a 30 month stability test 
of a 30% drug loaded ITZ:PVAL 4-88 composition shows that stable amorphous 
dispersions can be achieved. 
The KinetiSol® Dispersing (KSD) technology has been shown to create solid 
dispersion systems from challenging drugs and highly viscous polymers.  The focus has 
been primarily using this technology for solubility enhancement, but it can be advantageous 
for other obstacles facing the pharmaceutical development industry.  Chapter 4 contains an 
investigation into the use of the technology for producing abuse deterrent formulations for 
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the drug, theophylline, which is used as a model for oxycodone.  Various high molecular 
weight polymers are combined with plasticizers to produce mechanical and chemical 
properties sufficient to resist alcohol dose dumping, size reduction for immediate release 
and syringeability for injection.  Thus, the KinetiSol® Dispersing (KSD) technology can be 
used as a formulation platform for creating abuse deterrent delivery forms in addition to 
solid amorphous dispersions for solubility enhancement. 
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Chapter 1 
Amorphous Solid Dispersions and Nano-crystal Technologies for Poorly 
Water-Soluble Drug Delivery [1] 
[1] Previously published:  Brough, C. and R.O. Williams III, Amorphous solid 
dispersions and nano-crystal technologies for poorly water-soluble drug delivery. 
International Journal of Pharmaceutics, 2013. 453(1): p. 157-166. 
 Research and writing was supervised by Robert O. Williams III. 
1.1 INTRODUCTION 
Poorly-water soluble drug substances are a significant percentage of the molecular 
entities in the industry’s drug development pipeline and are a growing percentage of those 
commercially available [2-4].  In the past, the industry consensus was to view these as 
highly risky development candidates [5].  However, given their prevalence, industry 
consensus has shifted from an attitude of avoidance to one of acceptance as increasing 
research dedication is given to solving solubility challenges [6].  Whether the increase in 
number of poorly water-soluble entities is due to modern high-through put screening 
methodologies [7] or credited to development on increasingly biocomplex diseases 
requiring higher lipophilicity and larger molecular weight, the challenge of poor solubility 
is not disappearing in the foreseeable future [8, 9]. 
Addressing this issue, the pharmaceutical industry has developed multiple methods 
for increasing the apparent solubility of crystalline drugs.  Traditionally, salt formation was 
preferred by medicinal and synthetic chemists for weak bases or weak acids [10].  
Unfortunately, only 20-30% of new molecules form salts easily, so 70-80% of those entities 
must find another route to improved solubility [11].  Cyclodextrins [12], self-emulsifying 
drug delivery systems (SEDDS)[13], solid lipid nanoparticles [14], liposomes [15], 
micelles [16], soft gelatin capsules [17], co-crystals [18], pH micro-environmental 
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modifiers [19], and high energy polymorphs [20] are some of the routes available to 
pharmaceutical scientists.  However, the last decade has shown the prevalence of two 
solubility/dissolution rate improvement methods both in scientific literature and marketed 
products: nano-crystal delivery forms and solid amorphous dispersions. 
1.2 SCIENTIFIC FOUNDATION 
Solubility of the drug substances plays a significant role in its bioavailability.  The 
Biopharmaceutical classification system (BCS) was established in order to classify 
intestinal absorption [21].  Poorly water-soluble compounds are grouped into BCS Class II 
(high permeability, low solubility) or BCS Class IV (low permeability, low solubility) 
depending upon their permeability categorization [22].  
There are multiple complex factors in drug absorption, but a straightforward 
conceptual approach to understanding solubility’s role can be expressed by the maximum 
absorbable dose (MAD) formula: 
MAD =  𝐾𝑎 ∙ 𝑆𝑝𝐻 ∙  𝑉𝑆𝐼 ∙ 𝑡 
Equation 1.1: Maximum absorbable dose (MAD) formula. 
Where Ka is the intestinal absorption rate constant (related to permeability), SpH is 
the solubility at intestinal pH, VSI is the volume of fluid in the small intestine available for 
drug dissolution and t is the transit time through the small intestine [23, 24].  While this is 
a more simplistic model, it does illustrate important points in the challenge of poorly 
soluble drug absorption.  First, the solubility at the site of absorption is critical after the pH 
transition from the acidic gastric environment [25].  Delivery forms must either include 
dissolution in the gastric environment and maintenance of solubility through the pH 
transition into the intestines or acceptably rapid dissolution rates at intestinal pH to achieve 
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solubility during the intestinal transit time.  Second, Ka, the intestinal absorption rate, must 
also be considered with increased solubility.  At low solubility, the SpH is likely the limiting 
factor in the maximum absorbable dose.  If the drug solubility is increased substantially, 
the limiting factor can shift from solubility to the intestinal absorption rate [26].  Thus, it 
may be more important to stabilize drug solubility for the entire intestinal transit time rather 
than to maximize solubility for a portion of it. 
1.2.1 Nano-crystal Delivery Forms 
Both nano-crystal delivery forms and solid amorphous dispersions increase the 
amount of drug dissolved at the site of absorption, but they achieve this by different 
mechanisms.  Nano-crystal delivery relies on reduced particle size for increased solubility 
and dissolution rate [27].  The Nernst-Brunner equation (Noyes-Whitney equation 
modified with Fick’s second law) illustrates the effect of smaller particle size on dissolution 
as seen in Equation 1.2: 
𝑑𝐶
𝑑𝑡
=
𝐷𝑆
𝑉ℎ
(𝐶𝑠 − 𝐶) 
Equation 1.2: The Nernst-Brunner equation. 
Where dC/dt is the change of concentration over time (dissolution), D is the 
diffusion coefficient, S is the surface area, V is the volume of the dissolution medium, h is 
the thickness of the diffusion layer, CS is the saturation solubility and C is the instantaneous 
concentration at time t [28].  As particles are reduced in size the surface area increases; as 
particles are reduced to the nano scale the surface area increases dramatically.  In addition 
to affecting surface area, with particle sizes less than about 50µm the thickness of the 
diffusion layer appears to decreases as well [29].  Thus, nano sizing increases dissolution 
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by simultaneously increasing surface area in the numerator and decreasing the diffusion 
layer thickness in the denominator of Equation 1.2.  
The relationship of solubility of a small particle in a bulk solution is given by the 
Ostwald-Freundlich equation (Equation 1.3), which is analogous to the Gibbs-Kelvin 
equation [30]. 
ln (
𝑥𝑅
𝑥∞
) =
2σαγυ2
γ
𝑘𝐵𝑅𝑇
 
Equation 1.3: Ostwald-Freundlich equation. 
Where the solubility, xR, of a small solid particle (phase γ) in the ideal bulk solution 
(phase α) is related to radius, R.  The other variables are as follows: x∞  is the relative 
concentration of solute in phase α, σαγ is the surface tension of the solid particle at its 
boundary with phase α, υ2γ is the volume per molecule in the solid particle, kB is the 
Boltzmann constant and T is the temperature.  According to the equation, particles with a 
very small radius will have increased solubility.  This indicates that nanoparticles not only 
affect surface area, S, and the diffusion layer thickness, h, in the Nernst-Brunner equation, 
but also the saturation solubility, CS.  Entering values to simulate a drug in intestinal fluid 
(assuming a drug molecular weight of 500 and an σαγ value of 15-20 mN m-1 for the crystal-
intestinal fluid surface tension) Equation 1.3 predicts an approximate 10-15% increase in 
solubility for a particle size of 100 nm [31]. 
Further illustrations of increased solubility of small particles have been reported 
[32, 33].  Junghanns et al. used an equation related to the Ostwald-Freundlich equation, the 
Kelvin equation, which describes the relationship between the radius of a liquid droplet 
and the vapor pressure leading to evaporation. Equation 1.4 is the Kelvin equation. 
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ln (
𝑝
𝑝o
) =
2γ𝑉𝑚
 Ȓ𝑅𝑇
 
Equation 1.4: Kelvin equation. 
Where p is the vapor pressure, po is the saturated vapor pressure, γ is the surface 
tension, Vm is the molar volume, Ȓ is the universal gas constant, R is the radius of the droplet 
and T is the temperature.  Under the assumption that a transfer of molecules from a liquid 
phase to a gas phase is in principal identical to the transfer of molecules from a solid phase 
to a liquid phase, the properties of BaSO4 were entered into the Equation 1.4.  Using the 
curvature of the nanoparticle surfaces to estimate pressures, the Kelvin equation shows an 
increase in saturation solubility for particles smaller than 1 µm. 
Nanoparticles are much more unstable than microparticles because of the extra 
Gibbs free energy contribution related to reducing particle size and primarily due to surface 
energy [34].  Addressing this extra contribution is key to formulating pharmaceutical 
nanoparticles because they will tend to agglomerate to minimize their total energy [35].  
Approaches to stabilizing drug nanoparticles can be categorized into two groups: 
thermodynamic stabilization which uses surfactants or block copolymers for particle 
stability or kinetic stabilization which uses energy input to compensate for Gibbs free 
energy [34].  For maximum effectiveness, the two approaches are often combined [36].  
Careful selection of the amount of stabilizer is as important as the selection of the type of 
stabilizer.  For example, one obstacle to stabilization is Ostwald ripening, which is the 
phenomenon in which smaller particles in solution dissolve and deposit on larger particles 
in order to reach a more thermodynamically stable state by minimizing the surface to area 
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ratio [37].  Too little stabilizer allows agglomeration of nanoparticles and too much 
stabilizer promotes Ostwald ripening [38]. 
1.2.2 Amorphous Dispersions 
 Understanding the benefit of solid amorphous dispersions must be explained in 
terms of enthalpic energy.  There are three basic quantities governing the solubility (S) of 
a given solid solute [8]: 
 
𝑆 = 𝑓(𝐶𝑟𝑦𝑠𝑡𝑎𝑙 𝑃𝑎𝑐𝑘𝑖𝑛𝑔 𝐸𝑛𝑒𝑟𝑔𝑦 + 𝐶𝑎𝑣𝑖𝑡𝑎𝑡𝑖𝑜𝑛 𝐸𝑛𝑒𝑟𝑔𝑦 + 𝑆𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛 𝐸𝑛𝑒𝑟𝑔𝑦) 
Equation 1.5: Three basic quantities governing solubility. 
The crystal packing energy term accounts for the energy necessary to disrupt the 
crystal lattice and remove isolated molecules.  The cavitation energy term accounts for the 
energy required to disrupt water in order to create a cavity in which to host the solute 
molecule.  The solvation energy term accounts for the release of energy as favorable 
interactions are formed between the solvent and solute.  A graphical representation is 
shown in Figure 1.1. 
 
 
 
 
 
 
Figure 1.1:  Three basic quantities that determine solubility of solid solute. 
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In relative terms, the crystal packing energy is larger than both cavitation and 
solvation energies and thus, the driving force behind solubility.  The intent in formulating 
an amorphous solid dispersion is to minimize this energy component by disrupting the drug 
crystal lattice in the delivery form.  In conjunction with solubility enhancing polymeric 
carriers, the apparent solubility can be increased by up to 10,000 fold or more [39-42].  In 
terms of the Nernst-Brunner equation, drastic increases of the saturation solubility, CS, 
result in a much faster dissolution rate. 
Solid amorphous dispersions essentially contain stored potential energy that can 
‘spring’ the molecular entity into a supersaturated state [43, 44].  Since supersaturation is 
thermodynamically unstable, the formulation must also provide a ‘parachute’ to keep the 
solubility from rapidly returning to the crystalline drug equilibrium solubility (Figure 1.2) 
to maintain elevated drug concentrations for the duration of intestinal transit to achieve the 
maximum absorbable dose.  In general, solubility enhancing polymers are reported to 
function well as a parachute or stabilizer due to drug-polymer interactions in solution and 
by adsorption of the polymer on the growing crystal [45].  Other solubility enhancing 
formulations may require additional excipients to function as the parachute to retard the 
descent from high to low energy forms of the drug.  Examples of polymers that have been 
investigated for their stabilizing effect are PVP [46], PEG [47], methylcellulose (MC) [48] 
and HPMC [49]. 
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Figure 1.2:  ‘Spring & Parachute’ concept for supersaturation stability [44] (adapted). 
A concern with solid dispersions is the possibility of the amorphous drug substance 
undergoing crystallization on storage.  The effect of moisture on storage stability is an 
another concern because the presence of water may increase drug mobility and promote 
drug crystallization [50].  Additionally, some polymers used in solid dispersions are 
hygroscopic, which may result in phase separation, crystal growth or conversion from a 
metastable crystalline form to a more stable crystalline structure during storage [51].  This 
would result in continually decreasing the solubility and dissolution rate as well as lower 
the in vivo performance during the product’s shelf-life. 
The above challenges can be mitigated by proper polymer selection, drug loading 
optimization and appropriate product packaging selection.  Amorphous solid dispersions 
can be rendered physically stable via kinetic stabilization: i.e., freezing the amorphous drug 
substance in the polymer matrix to restrict molecular mobility to prevent nucleation and 
crystal growth.  It has been reported that for adequate kinetic stability, the Tg of the 
composite matrix should be 50 °C above the maximum storage temperature [52].  From 
this perspective, polymer selection is important to ensure a high composite Tg for the 
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preservation of the amorphous drug.  A polymer may also stabilize an amorphous drug 
substance via drug-polymer intermolecular interactions such as hydrogen bonding, Van der 
Waals forces, etc.  Such interactions can be estimated a priori utilizing calculated solubility 
parameters or empirically via the use of analytical techniques such as Fourier transform 
infrared spectroscopy (FTIR) [53-55].  These interactions provide thermodynamic stability 
to the amorphous drug substance and can result in product stability irrespective of Tg [56].  
Drug loading can impact both kinetic and thermodynamic stability of an amorphous solid 
dispersion.  For a low Tg drug in a kinetically stabilized dispersion, the higher the drug 
loading means the lower the composite Tg, and hence the more unstable the composition.  
For a thermodynamically stabilized amorphous solid dispersion, increasing drug loading 
can saturate bonding sites, and thus result in a less stable amorphous dispersion.  Practically 
speaking, most amorphous solid dispersions are formulated in a metastable region where 
the mode of stabilization is a combination of both kinetic and thermodynamic mechanisms 
[57].  As drug loading impacts both of these stabilizing mechanisms it is critical to conduct 
accelerated stability studies on a range of drug loadings to arrive at a physically stable 
amorphous dispersion with an acceptable drug load.  Finally, packaging is critical when 
the amorphous solid dispersion is susceptible to destabilization by moisture absorption 
[58].  Adsorbed moisture can lead to crystallization by plasticizing the polymer matrix and 
increasing the molecular mobility, displacing drug substances from bonding sites on the 
polymer, or both.  Utilizing the appropriate dosage form, the packaging configuration can 
eliminate moisture contact and stabilize the amorphous product for an acceptable shelf-
life. 
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1.3 PROCESSES 
1.3.1 Nano-crystal Technologies 
Wet ball milling (also called bead milling or pearl milling) is the most frequently 
used production method for drug nano-crystals in the pharmaceutical industry [59].  This 
can be attributed in part to the simplicity of the process allowing it to be performed in 
almost every lab.  The simplest way of doing ball milling is feeding coarse drug substance 
into a jar filled with milling media with at least one stabilizing agent.  Then, agitate the 
milling media by magnetic stirrer or by rotating or tumbling the jar.  This will generally 
yield very fine particles with a narrow size distribution when allowed to operate long 
enough. 
Alternatively, wet ball milling operations based on higher energy media movement 
can accomplish particle size reduction in times more suitable for industrial pharmaceutical 
applications [60].  The NanoCrystal™ process is a high energy wet ball milling process 
regarded as the standard procedure to produce nanosuspensions [61].  To operate, the 
milling chamber is filled with milling media, water, drug and stabilizer.  A shaft with 
projectiles spins within the milling chamber which allows drug particles to collide with the 
chamber wall, milling media and other drug particles.  The high shear forces provide the 
energy input to fracture drug crystals into nanometer-size particles.  Normal processing 
times ranging from 30 minutes to 2 hours yield nanosuspensions of good quality.  The 
process has demonstrated scalability; batch mode R&D equipment can process 10 mg of 
drug substance and larger continuous mode equipment is being used to produce 
commercial products [62].  Because it is part of the process, one inherent benefit of wet 
ball milling is creating a very stable aqueous suspension.  This suspension can be directly 
formed into liquid oral, injectable and nebulized inhalation delivery forms [63]. 
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High pressure homogenization can be considered the second most frequently used 
technique to produce nano-crystals [59].  Like wet ball milling, it is a particle size reduction 
technology, but uses jet-stream homogenization by pumping drug, dispersion medium, 
surfactants and/or stabilizers under high pressure through a micro fluidizing nozzle.  The 
particle size reduction is caused by cavitation forces, shear forces and collision through 
multiple homogenization cycles.   The number of passes depends upon many factors 
comprising the type of homogenizer and process conditions, which has led to various 
technologies: IDD-P™, Dissocubes® and Nanopure® [32]. 
Combination technologies have also been developed that integrate a pre-treatment 
step with a subsequent high energy step, like high pressure homogenization.  The 
NANOEDGE™ technology is one example that combines a first classical precipitation 
step with a subsequent annealing step by applying high energy (high pressure 
homogenization)[32].  The term annealing was used meaning nanoparticles achieve a lower 
surface energy by application of energy followed by thermal relaxation.  Other combination 
technologies, bottom-up methodologies and other processes are available to produce nano-
crystal drug delivery forms [64-66]. 
1.3.2 Amorphous Dispersion Technologies 
Processes for the preparation of solid amorphous dispersions can be categorized 
into two general types: solvent methods and fusion or melting methods.  With solvent 
methods, solid dispersions are obtained by evaporating a common solvent from a drug and 
carrier solution.  In general, fusion methods heat a drug and carrier composition above their 
melting or glass transition temperatures, mix at the elevated temperature, and then cool the 
composition in such a way to keep the active ingredient in its amorphous state.  Operating 
temperatures for solvent techniques are generally lower than fusion techniques and are 
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advantageous for thermolabile drug substances.  However, finding a common solvent is 
not always straightforward.  For example, in the case for solid dispersions for immediate 
drug release, hydrophobic drugs are typically combined with hydrophilic carriers, which 
can limit solvent selection.  A secondary drying step is often required to reduce residual 
solvent below accepted levels for safety issues.  In addition, small amounts of residual 
solvent could negatively affect drug chemical stability and can plasticize the solid 
dispersion matrix to subsequently impact physical stability [45]. 
Practical applications of the solvent method are spray drying and freeze drying.  In 
spray drying, the drug and carrier solution is atomized into hot gas that causes the solvent 
to evaporate resulting in spherical particles containing amorphous drug [67].  Freeze drying 
or lyophilization is a technique in which the drug and polymer solution is frozen and the 
solvent is sublimed under vacuum.  Another solvent method is using a fluidized bed system 
to coat multiparticulates (i.e., beads or pellets) with drug-carrier solutions resulting in 
pellets with a solid amorphous dispersion coating [68]. 
Hot-melt extrusion (HME), a well-known fusion technique, has been a topic of 
interest in recent pharmaceutical research literature [69].  HME is the process of pumping 
compositions through a heated barrel by one or more screws under pressure followed by 
discharging the extrudate through a die.  Solvents are not necessary thereby eliminating the 
aforementioned solvent related issues.  The intense mixing and agitation imposed by the 
rotating screw(s) causes uniform distribution of drug and the processes is continuous and 
efficient.  The extrudate discharge is dense and can be post-processed without the bulk 
density issues of some solvent methods.  Viscous compositions may require the aid of a 
plasticizing agent to allow the composition to flow through the heated barrel and out the 
die without over torqueing the electric motor.   Plasticizers increase molecular mobility 
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upon storage and can allow for crystallization if the composition’s glass transition 
temperature is not at least 50°C above the storage condition [52]. 
Other fusion processes have been explored in creating amorphous dispersions.  
Spray congealing is a process where molten compositions are atomized into particles of 
spherical shape and then cooled to solidification [70].  KinetiSol® Dispersing is a fusion 
based process that has been shown to create amorphous dispersions of high temperature, 
thermolabile drug substances without degradation [71].  It does not have the same viscosity 
limitations as HME and thus compositions are processed without the need of a plasticizer.  
Scalability is a non-issue as the equipment is used in non-pharmaceutical industrial 
applications, but no current marketed products are produced by this technology. 
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1.4 RESEARCH COMPARISONS 
Numerous papers have been published on amorphous solid dispersions and nano-
crystal formulations.  For the purposes of this comparison review, only original research 
papers that directly compare the two in a formulation development effort are discussed.  
Additionally, literature was limited to those studies that included participation and/or 
support from a pharmaceutical company as this was considered to be an indicator of the 
study’s commercial relevance. 
Fakes et al reported on the enhancement of an HIV-attachment inhibitor, BMS-
488043 [72].  The molecule was classified as a BSC class II compound with low aqueous 
solubility of 0.04 mg/ml and a permeability of 178 nm/s in a caco2 cell-line model.  To 
increase bioavailability of the molecule, a nanosuspension formulation was developed and 
compared to an amorphous solid dispersion made by a solvent evaporation method.  The 
nanosuspension formula was produced by a Nanomill™ at a 10% (w/w) concentration 
using hydroxypropyl cellulose (HPC-SL) at 2% (w/w) and sodium lauryl sulfate (SLS) at 
0.1% (w/w).  The mean cumulative particle size was 0.120 µm and the suspension was 
physically stable when stored at room temperature up to 4 weeks.  
The amorphous dispersion was produced by flash evaporation from an acetonitrile 
solution in a Buchi Rotovap.  Polyvinylpyrrolidone (PVP, K-30) was the selected polymer 
with drug loadings of 20 and 40%.  The dispersions were determined to be XRD amorphous 
following storage at 50 °C up to 3 weeks.  Further, an extremely high drug load amorphous 
dispersion of 80/20 BMS-488043/PVP was found to remain amorphous after storage at 50 
°C for 17 weeks.  The two amorphous formulations and a single nanosuspension formula 
were compared to wet-milled crystalline drug capsule in a crossover beagle dog study.  The 
two solid dispersions were dosed as 200 mg tablets with the nanosuspension administered 
via a standard gavage tube at the equivalent dose.   The nanosuspension showed a 4.7 fold 
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increase in Cmax and 4.6 fold increase in AUC over the capsule.  The 20% amorphous 
dispersion showed an 18.2 and 7.0 fold increase in Cmax and AUC respectively.  The 40% 
dispersion showed a 15.7 fold increase in Cmax and 8.7 fold increase in AUC.  The authors 
concluded that the amorphous dispersions were the superior option for increased 
bioavailability of BMS-488043. 
Zheng et al reported on the commercial development of LCQ789, a BCS Class II 
compound, investigated particle size reduction, amorphous dispersions, lipid based 
formulations and co-crystals [73].  LCQ789 is a crystalline, neutral compound with a 
molecular weight of 476.93 and a ClogP of 5.4 with extremely low solubility (<1 µg/ml).  
Each formulation method was carefully screened: co-crystal screening was performed with 
four solvents and 27 co-crystal formers, solid dispersion screening was conducted with 
seven polymers and a total of 64 variants, and lipid-based formulations were screened with 
25 GRAS listed excipients.  Particle size reduction on a research compound from the same 
scaffold at LCQ789 showed minimal impact on its oral bioavailability, as confirmed by 
GastroPlus™ and in vivo rat study.  Consequently, the nanoparticle approach was not 
pursued for LCQ789. 
Optimized formulations were compared in rat and dog single dose pharmacokinetic 
studies.  Minimal exposure was observed with suspensions of crystalline LCQ789 and co-
crystal formula in rats, but the co-crystal did show some improved exposure in dogs.  In 
both species, significant improvement in bioavailability was achieved with the solid 
dispersion and lipid-based formulations.  The in vivo pharmacokinetic studies indicated 
that the solid dispersion improved the oral bioavailability by 18-fold in rats and 50-fold in 
dogs, while the lipid-based formula increased the oral bioavailability by 25-fold in rats and 
80-fold in dogs.  The lipid-based formula achieved the highest exposure, and the solid 
dispersion demonstrated less inter-subject variability.  These two formulas continued on to 
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dose escalation studies.  Higher exposure was achieved with the lipid-based formula, but 
it also exhibited higher variability as compared to the solid dispersion.  In addition, overall 
high organic content was a concern for the long-term safety studies.  As a result, the solid 
dispersion formulation was selected for use in safety studies. 
Vogt et al investigated micronization, co-grinding and spray-drying formulations 
of fenofibrate and compared their release profiles to German and French commercial 
products [74].  Micronization was conducted by jet milling while nanosizing was 
performed by bead milling.  Co-grinding was achieved by particle size reduction with 
lactose, polyvinylpyrrolidone (PVP), sodium lauryl sulphate (SLS) and combinations of 
the three excipients.  Spray dried particles were produced by bead milling with lactose and 
SLS in water, then fed directly into a Buchi Mini Spray Dryer.  All formulations were 
compared by dissolution in biorelevant media.  The fenofibrate drug products 
commercially available on the German and French markets dissolved similarly to crude or 
micronized fenofibrate and were slower than the co-ground and spray-dried formulas.  The 
co-ground formulations had faster dissolution rates, but reached the same equilibrium 
concentration as the commercially available products.  The spray-dried formula produced 
substantial initial supersaturation, but returned to concentrations only slightly better than 
equilibrium in 180 minutes because formulation did not contain a parachute component.  
This was termed as unstable by the authors, but they concluded that both co-grinding and 
spray-drying could potentially lead to better bioavailability of fenofibrate drug products. 
Kwong et al reported that toxicity is one of the leading causes of attrition in the 
clinic, and that good safety margins are imperative to reach proof of concept in clinical 
studies [75].  Research was conducted to identify a conventional formulation that would 
provide the maximum exposure possible to define the dose limiting toxicity for a molecule 
referred to as compound 3.  Compound 3 existed as a crystalline free base with poor 
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solubility in water (0.0002 mg/ml in water, 0.0003 mg/ml in SGF and 0.004 mg/ml in 
FaSSIF), but was highly permeable.  Thus, drug dissolution was the rate limiting step for 
absorption.   
 
 
 
 
 
 
 
 
Figure 1.3:  Dose proportionality of compound 3 in 10% Tween (-▲-) as the crystalline 
form; in 0.5% Methocel/0.24% SLS as the amorphous form (-■-) and in 
solid dispersion at 50% drug loading in HPMC-AS given as suspension in 
Methocel (-●-) from 10 mpk to 750 mpk dosed at 5 ml/kg in Sprague 
Dawley rats (n=4) [75] (corrected). 
Various preparation methods and excipients were screened and the leading 
formulations were compared in a preclinical dose range finding study in rats.  The three 
leading formulas were (1) crystalline form in 10% Tween 80, (2) amorphous form in 0.5% 
methylcellulose and 0.24% sodium lauryl sulfate and (3) a solid dispersion with 50% drug 
loading in HPMCAS-HF as seen in Figure 1.3.  The particle size for compound 3 was not 
specifically mentioned; however, looking at another reported project within the article, the 
particle size is conservatively below 10 µm.  At the lowest dose, 10 mpk, the exposure was 
similar for all three compounds.  As the dose was increased to 100 mpk, the solubility of 
the crystalline phase limited the absorption of the compound and resulted in a lower 
exposure.  It is interesting to note that the exposure obtained from the amorphous form is 
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comparable to the solid dispersion at this level.  Finally, at 750 mpk the amorphous 
dispersion provided a significant increase in exposure over the other two formulations (4x 
AUC as compared to the crystalline phase). 
Thombre et al compared amorphous, nanocrystalline and crystalline formulations 
of ziprasidone to commercially available Geodon® capsules in order to minimize food 
effect [76].  The three formulations in the study were (A) an amorphous inclusion complex 
of ziprasidone mesylate and a cyclodextrin, (B) a nanosuspension of crystalline ziprasidone 
free base made by wet-milling, and (C) jet-milled ziprasidone HCl coated crystals made by 
spray drying the drug with hypromellose acetate succinate.  The pharmacokinetic studies 
in dogs showed that the three formulations performed differently.  Formulation B yielded 
the best fasted state absorption enhancement, indicating that improved dissolution rate with 
a low potential for precipitation might be the best combination to improve ziprasidone 
absorption in the fasted state.  The in vivo data for formulation B was highly variable, but 
the mean summary parameters were comparable to the control capsule dosed in the fed 
state. 
Formulation A also showed increase absorption of ziprasidone in the fasted state 
compared to the commercial capsule.  Because of the solubilization technology used, 
ziprasidone likely went quickly into solution and was absorbed (formulation A had the 
shortest observed Tmax).  But, the extent of absorption was less than the control capsule 
dosed in the fed state, indicating possible precipitation in intestinal pH media.  In vitro 
testing demonstrated that some amorphous complex formulations can achieve high enough 
supersaturation to cause precipitation of a lower solubility drug form such as the free base.  
Formulation C did not show enhanced absorption in the fasted state compared to the 
commercial capsule control. 
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In humans, both formulations A and B showed improved absorption in the fasted 
state while formulation C did not [77].  Thus, the in vivo performance in dogs was 
qualitatively similar to the in vivo performance of these formulations in humans. 
Sigfridsson et al compared crystalline and amorphous nanosuspensions to a 
solution of AZ68 [78].  AZ68 is a neurokinin NK receptor antagonist intended for 
schizophrenia treatment.  The compound has high permeability and low solubility in the 
gastrointestinal track and thus fulfills the criteria for a BCS II compound.  Crystalline 
nanosuspensions were prepared by bead milling; amorphous nanosuspensions were 
prepared by a solvent evaporation process and confirmed amorphous by XRPD (Powder 
X-ray Diffraction).  Particle sizes for both suspensions were approximately 200 nm and 
both formulations were dosed in rats by gavage at similar concentrations.  The results 
indicate that AZ68 is absorbed at a lower rate for crystalline nanosuspensions compared to 
amorphous nanosuspensions and solutions.  However, the absorbed extent of the 
compound is similar. 
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1.5 MARKETED PRODUCTS 
1.5.1 Nano-crystal Products 
Perhaps the best way to understand the utility of a technology is to review its 
application in marketed products. Table 1.1 contains examples of current marketed 
products produced using nano-crystal technologies. 
Table 1.1: Examples of commercial nano crystal products [59] 
The first commercial product using a pure nanoparticle technology was 
Rapamune®, a tablet formulation containing the immunosuppressant drug, sirolimus.  It 
was originally marketed as an unpleasant tasting lipid based liquid solution that required 
cold storage and a dispensing protocol.  Sirolimus is poorly water soluble (~2 µg/ml) and 
processed by NanoCrystal® technology into a fine nanoparticle dispersion with a mean 
particle size of <200 nm.  The NanoCrystal Colloidal Dispersion® intermediate is then post 
processed into tablets of 1 mg, 2 mg and 5 mg.  The tablets have increased bioavailability 
(~ 27%), do not require special storage conditions and have better patient compliance due 
to a more convenient dosage form [62, 79]. 
The second product, Emend®, is an antiemetic for the prevention of nausea and 
vomiting following chemotherapy and surgery.  It is a spray coated capsule formulation of 
aprepitant that has been formulated as a nanosuspension.  Aprepitant (water solubility 3-7 
Trade Name Generic Name Processing Technology Company FDA Approval 
Rapamune Sirolimus NanoCrystal Pfizer (Wyeth) 2000 
Emend Aprepitant NanoCrystal Merck 2003 
Tricor Fenofibrate NanoCrystal Fournier Pharma (AbbVie) 2004 
Triglide Fenofibrate IDD-P Sciele Pharma, SkyePharma 2005 
Megace ES Megestrole acetate NanoCrystal PAR Pharmaceuticals 2005 
Invega Sustenna Paliperidone palmitate NanoCrystal Janssen 2009 
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µg/ml) is a free base crystalline compound that was processed into a fine particle dispersion 
using a wet milling technology, and then processed into a solid dosage capsule formulation.  
The original dosage form showed significant food effect with exposures of 3-fold increase 
under fed conditions for a 100 mg dose.  The food effect was significantly higher at a 300 
mg dose [80]. The NanoCrystal® formulation was able to eliminate the food effect by 
increasing surface area 40 fold which resulted in a 4 fold increase in AUC values in the 
fasted state of beagle dogs.  The elimination of the food effect for antiemetic drug is 
significant as the commercial success may have been limited if required to consume with 
food [62]. 
Tricor® is the successor product for fenofibrate (for hypercholesterolemia) after 
patent expiration.  Triglide is also a fenofibrate nano-crystal product, but produced by the 
IDD-P® technology.  Tricor® has a dose of 48 mg or 145 mg in a tablet form. The nano-
crystal technology provided a life-cycle extension in the creation of a superior performing 
product.  Fenofibrate showed 35% higher absorption in the fed state and significantly 
reduced the food effect [32]. 
Megace ES® (ES stands for enhanced solubility) is for the delivery of megestrol 
acetate, a synthetic progestin used to treat anorexia, cachexia and AIDS-related wasting.  
The commercial formulation is an aqueous nanosuspension.  The dose is 625 mg/ 5 ml and 
the nanosuspension reduces bioavailability differences between fed and fasted conditions.  
It also has less administration volume than the previously given oral formulation (only ¼) 
while being less viscous [32]. 
The last approved nano-crystal product to be discussed is Janssen’s INVEGA® 
SUSTENNA®. This product, an atypical antipsychotic, is a once monthly intramuscular 
extended release injectable dosage form of paliperidone palmitate.  It is a liquid dispersion 
product in prefilled syringes that has physical stability without the need for special storage 
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conditions for a two year shelf life.  This is a sterile product by way of conventional 
sterilization methods.  Terminal heat is the preferred route, but filtration, gamma irradiation 
and aseptic approaches are employed as alternatives [81].  The particulate nature of the 
formulation allowed for sustained release and in a patient population where compliance is 
a concern, the once a month dosage is a valuable option [62]. 
1.5.2 Amorphous Dispersion Products 
Table 1.2 contains examples of current marketed products produced using solid 
amorphous dispersion technologies. 
Trade Name Generic Name Processing Technology Company FDA Approval 
Cesamet Nabilone Solvent evaporation Meda Pharmaceuticals 1985 
Sporanox Itraconazole Fluid bed bead layering Janssen 1992 
Prograf Tacrolimus Spray drying Astellas Pharma 1994 
Kaletra Lopinavir, ritonavir Melt extrusion AbbVie 2007 
Intelence Etravirin Spray drying Janssen 2008 
Zortress Everolimus Spray drying Novartis 2010 
Norvir tablet Ritonavir Melt extrusion AbbVie 2010 
Onmel Itraconazole Melt extrusion Merz Pharma 2010 
Incivek Telaprevir Spray drying Vertex 2011 
Zelboraf Vemurafenib Solvent/anti-solvent precipitation Roche 2011 
Kalydeco Ivacaftor Spray drying Vertex 2012 
Table 1.2: Examples of current amorphous dispersion products  [82] (modified). 
The original solid oral formulation of Kaletra® was a soft-gelatin capsule (SGC) 
containing 133.3 mg of lopinavir (an HIV protease inhibitor) with 33.3 mg of ritonavir, 
with ritonavir acting as a bioavailability enhancer for lopinavir [83].  The SGC dosage form 
required refrigeration and the recommended adult dosage was 6 capsules daily with food 
to maximize the bioavailability of lopinavir.  Toward the end of end of enhancing therapy 
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with Kaletra, the product was reformulated as a solid amorphous dispersion utilizing HME 
technology. The result was a 200/50 mg lopinavir/ritonavir tablet formulation that reduced 
the number of dosage units and eliminated the requirement for refrigeration.  Compared 
with the SGC formulation, the HME formed tablet resulted in more consistent lopinavir 
and ritonavir exposures across meal conditions, which minimized the likelihood of extreme 
high or low blood plasma concentrations.  In addition, the removal of the refrigeration 
requirement allowed for worldwide distribution into underdeveloped areas that could not 
support a cold distribution chain. 
The path toward the development of ritonavir into a solid oral dosage form based 
on amorphous solid dispersion technology was very similar to that of Kaletra.  Ritonavir 
was originally developed because it possesses anti-HIV activity, but it is no longer 
prescribed as a sole protease inhibitor in antiretroviral regimens today.  However, as a 
pharmacokinetic enhancer, ritonavir has become a mainstay in the management of both 
treatment-naïve and treatment-experienced patients.  The basis for this enhancement is the 
inhibition of cytochrome P-450 (CYP) metabolic pathways [84].  Inhibition of CYP 3A4 
leads to a reduction in the metabolism of most protease inhibitors and increases 
pharmacokinetic properties including area-under-the-plasma concentration curve (AUC), 
maximum plasma concentration (Cmax), and half-life (t½).  These enhancements allow for a 
reduction of pill burden, dosing frequency and food restrictions while maintaining efficacy. 
Because ritonavir is not bioavailable in the crystalline solid state, it was formulated 
in ethanol/water based solutions.  It was available as an oral solution in 1996 and as SGC 
since 1998.  Only one crystal form of ritonavir was identified during development and the 
initial 240 lots of Norvir® capsules had no stability problems [85].  However, in mid-1998 
several lots of capsules failed the dissolution requirement and investigation revealed a 
polymorph with greatly reduced solubility compared to the original crystal form.  Within 
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weeks, this new polymorph (Form II) appeared throughout both the bulk drug and 
formulation areas.  Since the manufacturing of Norvir® capsules required a certain 
concentration in the ethanol/water solutions, Form II made the formulation unproducible. 
With the emergence and dominance of polymorph Form II, Abbott Laboratories 
reevaluated their manufacturing process [86].  They reported a new method to control the 
conversion of Form I to Form II by choosing an appropriate ratio of solvent to antisolvent 
in a reactor process.  Following the HME formulation development for Kaletra® in 2005, 
Abbott began developing a 100 mg HME-based amorphous dispersion formula for 
ritonavir.  In the bioequivalence studies, the HME tablet demonstrated equivalence with 
SGC for AUC parameters.  However, the ritonavir tablet Cmax was 26% higher than the 
SGC formulation [84].  This increase in Cmax was not expected to alter the safety or 
pharmacokinetic enhancing profile of ritonavir.  The tablet also exhibits less food effect 
than the SGC formulation. 
Itraconazole is another interesting example of a drug product that was 
commercialized using an amorphous solid dispersion technology.  The compound is a 
potent broad-spectrum triazole antifungal drug, is insoluble in water (solubility ~4 ng/ml) 
and was among the first marketed solid amorphous dispersion products.  Itraconazole is so 
insoluble in intestinal fluids that drug therapy with the compound could not be achieved 
without substantial solubility enhancement by formulation intervention. The original solid 
oral formulation, Sporanox® Capsule, was produced by a fluid bed bead layering process 
that used a co-solvent system of dichloromethane and methanol to dissolve itraconazole 
and hydroxypropyl methylcellulose (HPMC) which was then sprayed on inert sugar 
spheres [87].  The resultant product provided a significant enhancement of itraconazole 
bioavailability with approximately 55% of the administered dose absorbed [88].  
Itraconazole has recently been reformulated into a tablet composition that contains an 
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amorphous dispersion in HPMC 2910 by HME utilizing the MeltRx Technology®.  The 
trade name is Onmel®; it is available in a 200 mg strength for once-daily administration 
and was approved by the FDA in April 2010 for the treatment of onychomycosis.  The 
HME formulation not only eliminated the use of organic solvents in manufacturing, but 
also reduced dosing frequency from twice-daily to once daily [89]. 
Like itraconazole, Zelboraf™ is another compound for which the drug therapy was 
enabled by the application of amorphous solid dispersion technology.  The product is a 
tablet dosage form containing an amorphous dispersion of vemurafenib in HPMCAS-LF 
produced by a solvent/anti-solvent precipitation called microprecipitated bulk powder 
(MBP) technology [90].  The process utilizes N,N-dimethylacetamide to dissolve the drug 
and the ionic polymer.  The solution is precipitated into acidified aqueous media, the 
precipitates are then filtered, repeatedly washed to remove residual acid and solvent 
content, dried, and then milled to form the amorphous powder intermediate, MBP.  The 
MBP product provides substantial enhancement of the solubility/ dissolution properties 
and oral bioavailability of vemurafenib with excellent physical stability.  The stability of 
the amorphous dispersion is attributed to the high composite Tg, intermolecular interactions 
between the drug and polymer as well as the moisture protective effect provided by the 
polymer. 
In initial Phase I clinical studies with a conventional formulation of vemurafenib, 
patients did not respond, i.e. no tumor regression, to doses as high as 1,600 mg [91].  The 
issue was identified as low oral bioavailability stemming from poor solubility, which 
caused a halt to the clinical study until it could be reformulated into a more bioavailable 
form.  Due to melting point and organic solubility limitations, traditional amorphous solid 
dispersion processes could not be applied, therefore necessitating the application of the 
MBP technology.  When clinical trials resumed with the new MBP-based formulation, 
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substantial tumor regression was achieved in a majority of patients as a result of the 
enhanced formulation [92].  The application of the MBP technology to vemurafenib is a 
compelling case study for the application of amorphous solid dispersion technology 
because formulation intervention was directly responsible for enabling the drug therapy 
and prolonging the lives of terminal patients suffering from metastatic melanoma. 
 
 
 
 
 
 
 
 
 
Figure 1.4: Timeline of FDA approved amorphous dispersion and nano-crystal 
products. 
In concluding this section, viewing the nano-crystal and amorphous dispersion 
FDA approved products on a timeline might indicate a possible trend in the drug 
development industry (see Figure 1.4).  From this analysis, it appears poorly water-soluble 
drug candidates were formulated for commercialization in the 1980s and 1990s using solid 
amorphous dispersion technologies.  In the late 1990s it seems as if the industry turned to 
nano-crystalline technologies as the method of choice for development of BCS class II and 
IV active ingredients.  However, from 2006 to 2012 only one nano-crystal product was 
approved by the FDA while 8 amorphous solid dispersion products were accepted.  
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Additionally, the last two FDA approved nano-crystal products were suspensions; the last 
one being an intramuscular injection product. This is a small sampling, but it looks like the 
current industry preference for solving water-solubility challenges for oral delivery is 
through the use of amorphous solid dispersion technologies. 
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1.6 CONCLUSION 
Nano-crystal delivery forms and amorphous solid dispersions are well established 
techniques for addressing poor water solubility in pharmaceutical compounds, however, 
the methodologies are quite different. While several marketed products are made by both 
nano-crystal technologies and amorphous solid dispersion technologies, it appears there 
are more amorphous dispersion products on the U.S. market today.  A timeline of FDA 
approved drugs suggests current industry preference for solving solubility challenges for 
oral delivery is leaning toward amorphous solid dispersion technologies. 
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Chapter 2 
New Use of Polyvinyl Alcohol as a Solubility Enhancing Polymer for 
Poorly Water-soluble Drug Delivery (Part 1) 
2.1 INTRODUCTION 
Poor water solubility has been documented as a common characteristic for new 
chemical entities in development pipelines and commercially available products in the 
pharmaceutical industry today [2-4].  Among the options for dealing with poor solubility, 
the incorporation of the drug substance in a solid amorphous dispersion dosage form is 
gaining popularity.  There are many reasons for this increase in popularity with only a few 
being mentioned here.  First, conventional chemistry methods for solubility enhancement 
like salt formation reportedly only work for 20-30% of new molecules, leaving the 70-80% 
remaining to find other routes to improved solubility [11].  Second, solid dispersions 
containing solubility enhancing polymers can dramatically increase apparent solubility for 
durations sufficient to enable absorption form the intestinal lumen.  Specifically, in the case 
of ITZ, solubility increases of 10,000 fold or more have been demonstrated [40-42].  Third, 
nano-crystal technologies have not proven as capable and industry trends show preference 
to solid dispersions [1].  Fourth, compared with other noncrystalline drug delivery 
approaches such as cosolvent systems or self-emulsifying drug delivery systems (SEDDS), 
amorphous solid dispersions are more amenable to be developed into tablets, which is the 
preferred solid dosage form for distribution, and amorphous dispersions demonstrate 
highly desirable advantages over liquid or semisolid formulations including lower 
manufacturing cost, smaller pill burden, and improved physical and chemical stability [57].  
Finally, the various grades of polymers used for solid dispersions can not only increase 
solubility, but also allow for targeted release and the tailoring of release profiles of a drug 
substance.  Thus, solving multiple problems simultaneously. 
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While numerous studies have been published on amorphous solid dispersions, there 
are a limited number of polymers suitable for creating those systems.  Polymers that have 
been reported as a major component in solid dispersion formulations for improved 
solubility are as follows: povidone (PVP) [93], copovidone (PVPVA) [94], crospovidone 
(CrosPVP) [95], polyethyleneglycols (PEG) [96, 97], polymethacrylates [98, 99], 
hydroxypropylmethylcellulose or hypromellose (HPMC) [87, 89], hypromellose acetate 
succinate (HPMCAS) [100, 101], hypromellose phthalate (HPMCP) [102], 
hydroxyethylcellulose (HEC) [103], hydroxypropylcellulose (HPC) [104], polyvinyl 
acetate phthalate (PVAP) [42], cellulose acetate phthalate (CAP) [42], poloxamers [105], 
carbomers [106], and Soluplus® [107].  As additional polymers are identified as options, a 
broader range of challenging drug substances may be enabled for oral delivery systems.  
Furthermore, existing prohibitive intellectual property could be circumvented and unique 
release profiles could be created.  Due to the high cost of development and regulatory 
compliance verification, repurposing an existing excipient would seem a financial and time 
efficient path. 
Polyvinyl Alcohol (PVAL) is a water-soluble synthetic polymer represented by the 
formula (C2H4O)n.  The value of n for commercially available materials is between 500 and 
5,000, which is roughly equivalent to a molecular weight range of 20,000 to 200,000 [108].  
PVAL is unique among the vinyl polymers in the fact that the monomer, vinyl alcohol, 
cannot exist in the free form.  So, it is manufactured by the polymerization of vinyl acetate 
and then converted by a hydrolysis (alcoholysis) process.  Various grades based on extent 
of hydrolysis exists with unconverted fractions being polyvinyl acetate.  Since EMD 
Millipore PVAL was used in this research, a brief explanation of their nomenclature is 
prudent.  Each grade of PVAL has two groups of numbers separated by a dash.  The first 
group of numbers represents the viscosity of the 4% aqueous solution at 20 °C as a relative 
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indication of the molar mass.  The second group of numbers is the degree of hydrolysis of 
the polyvinyl acetate.  For example, an 88 in the second group would represent 88% 
hydrolysis with 98% being considered a fully hydrolyzed grade.  Thus, a 5-88 grade would 
have the viscosity of 5 mPa·s in a 4% aqueous solution at 20 °C with the polymer chain 
being approximately 88% PVAL and 12% polyvinyl acetate [109]. Table 2.1 contains 
additional properties. 
Available molecular weights 14,000 – 205,000 g/mol for partially hydrolyzed grades; 16,000 – 195,000 for 
fully hydrolyzed grades. 
Crystallite melting point (Tk) 180 – 240 °C 
Glass transition temperature (Tg) 40 – 80 °C 
Percent crystallinity Varies; increases with percentage hydrolysis. 
Solubility in water 
Solutions can be prepared at any concentration.  However, because viscosity 
rises rapidly with solids content, certain practical limits exist for processable 
solutions. 
Solubility in organics Insoluble in most organic solvents.  Slightly soluble in ethanol, practically 
insoluble in acetone. 
Temperature onset of degradation Approximately 180 °C 
Aqueous solution pH (4% solution at room temperature) 5.0 – 6.5 
Hygroscopicity 
DVS measurements reveal below a relative humidity of 50%, the change in 
mass is less than 1%.  At 90% relative humidity, mass changes of 8 – 17% 
depending upon polymer type. 
Table 2.1: Properties of PVAL (EMD Millipore) [109] 
PVAL is currently being used in a variety of pharmaceutical applications.  It is used 
as a stabilizing agent for emulsions [110], in topical pharmaceutical [111] and ophthalmic 
formulations [112, 113].  It is used in artificial tears [114] and integrated into contact lenses 
for lubrication purposes [115].  Polyvinyl alcohol can be made into microspheres [116] and 
is used as an emulsifier in creating PLGA nanoparticles [117, 118].  It has also been used 
in sustained-release formulations for oral administration [119] and transdermal patches 
[120].  Oral toxicity has been evaluated and found safe even at high levels of consumption; 
 48 
the no-observed-adverse-effect level (NOAEL) for rats in a 3 month study was 5,000 
mg/kg body weight / day [121]. 
To the authors’ knowledge, PVAL has not been reported as the polymeric carrier 
in binary amorphous solid dispersions [122].  A brief discussion of the limitations of 
conventional methods for creating amorphous dispersions provides insight to probable 
reasons for this.  Solvent processes (e.g., like spray drying and precipitation approaches) 
require a drug/polymer solution prepared with a common solvent or co-solvents.  PVAL is 
insoluble in most organic solvents and only slightly soluble in ethanol while typical 
pipeline drug molecules are only slightly soluble in more aggressive organic solvents.  
Even if suitable solvents were ascertained, the required concentration of polymer would 
render the solution too viscous for practical processing (like preventing flow through a 
small orifice needed for spray drying).  Alternatively, the application of conventional 
fusion processes like hot melt extrusion (HME) and injection molding is limited due to the 
high melting point of PVAL and high viscosity of the resulting melt.  These technologies 
are not suitable for processing thermally sensitive and viscous formulations, however 
KinetiSol® has been demonstrated in these applications [123].  KinetiSol® Dispersing is a 
novel fusion process that does not have torque limitations like HME and has been shown 
to create unique solid dispersions [71].  Through this enabling technology, solid amorphous 
dispersions containing PVAL as the primary polymer can now be evaluated. 
The pH independence of PVAL presents some advantages in bioavailability 
enhancement.  The dissolution of pharmaceutical excipients with pH dependent ionizing 
properties can be variable across the gastrointestinal pH range [124].  For example, 
dissolution rate and apparent solubility of weakly basic drugs in gastric pH and weakly 
acidic drugs in intestinal pH would be higher due to the ionization at those pH conditions 
[40, 41, 125].  Anionic and cationic polymers are prone to those same ionization effects, 
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which allows for differing dissolution rates across the gastrointestinal tract.  This may 
become clinically significant for formulations utilizing ionic polymers in both inter-patient 
and intra-patient variation.  The dissolution behavior of non-ionic polymers is expected to 
be the same across the gastrointestinal track, which should lower variability and provide a 
more predictable bioavailability improvement [126].  Anionic polymers, even with 
variation challenges, are still often chosen in formulation development due to their ability 
to improve solubility compared to non-ionic polymers [127].  Anionic polymers have been 
shown to increase dissolution rate and apparent solubility of both weakly basic and neutral 
drugs in amorphous dispersions due to polymer/drug interactions likely occurring between 
polymer functional groups and the drug substance [128].   The few non-ionic polymers 
used for solid dispersions, primarily HPMC, PVP and PVPVA, do not exhibit tunable ratios 
of hydrogen bond donors and receptors like HMPCAS and polymethacrylates.  However, 
PVAL has a tunable density of hydrogen bond donating hydroxyl groups and hydrogen 
bond receptors along its polymer backbone while still having pH independent solubility.  
In theory, this would allow it to function strongly as a solubility enhancer like the anionic 
polymers, but also have the low variability of the non-ionic polymers. 
It is hypothesized that the pH independent solubility along with tunable density of 
functional groups of PVAL would be ideal in the creation of solid dispersions especially 
for weakly basic drugs.  While other groups have shown stability with semicrystalline 
polymers, PVAL will need be investigated to establish the polymer crystalline structure 
does not create nucleation sites for drug recrystallization during processing and storage 
[129]. As a first step in investigating that PVAL will function as a solubility enhancing 
polymer, ITZ was selected as the model drug to be formulated in various grades.  Varying 
molecular weight grades with identical degree of hydrolysis were used to create solid 
dispersions to determine its effect on performance.  Conversely, the best performing 
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molecular weight range of PVAL from the first group of formulations were selected in 
grades of changing degrees of hydrolysis.  The best performing polymer grade would then 
be compared to commercially available ITZ products. 
  
 51 
2.2 MATERIALS 
Itraconazole was purchased from Hawkins, Inc. (Minneapolis, MN).  All grades of 
EMD Millipore PVAL were donated by Merck Millipore.  All other chemicals used in this 
study were ACS grade. 
2.3 METHODS 
2.3.1 KinetiSol® Dispersing (KSD) 
All compositions for this study were produced by a lab scale, GMP pharmaceutical 
compounder designed and manufactured my DisperSol Technologies, L.L.C. 
(Georgetown, TX, USA).  Prior to KSD processing, materials were weighed, placed into a 
polyethylene bag, manually shaken for approximately 1 minute, and charged into the 
compounder chamber.  During processing, real time computer controls monitor various 
parameters and eject the material at a pre-set ejection temperature.  Discharged material 
was immediately quenched in a cooling die under pressure in a pneumatic press.  Cooled 
material was then milled in a FitzMill L1A and screened through a 60 mesh screen (250 
µm).  All further analyses was conducted on this powder. 
2.3.2 Differential Scanning Calorimetry (DSC) 
Modulated DSC analysis was conducted using a TA Instruments Model mQ20 DSC 
(New Castle, DE) equipped with a refrigerated cooling system and auto sampler. Samples 
were weighed to 5 - 10 mg in aluminum-crimped pans. Samples were heated at a ramp rate 
of 10 °C/min from 0 to 210 °C with a modulation temperature amplitude of 1.0 ºC and a 
modulation period of 60 seconds for all studies. Ultrahigh purity nitrogen was used as the 
purge gas at a flow rate of 50 mL/min. All data analyses were performed using TA 
Universal Analysis software. The thermogram for amorphous ITZ used in the DSC analysis 
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of the solid dispersions formulations was obtained on a second heating of crystalline ITZ 
following an initial heating to 200 ºC followed by rapid cooling (40 ºC/min) to 0 ºC. 
2.3.3 Powder X-Ray Diffraction (XRD) 
An Inel Equinox 100 X-ray diffractometer (INEL, Artenay, France) was used to 
detect the presence of ITZ crystallinity.  Milled compositions, physical mixtures or 
unprocessed ITZ were loaded on a rotating aluminum sample holder and placed in the 
radiation chamber.  The Equinox 100 utilizes Cu K Alpha radiation (λ = 1.5418 Å) with a 
curved radius detector to simultaneously measure a 2ϴ range of 5 - 110°.  Operating voltage 
and amperage were adjusted to 41 kV and 0.8 mA respectively and the scan time for each 
sample was 10 minutes. 
2.3.4 Polarized Light Microscopy (PLM) 
While XRD has been shown to have limits of detection of less than 1% [130], PLM 
can serve as a qualitative confirmation of XRD results.  PLM analysis was conducted on a 
Meiji Techno MT 9300 Polarizing microscope with a first order red compensator.  
Pulverized samples were dusted on a glass slide and viewed under 400x magnification.  
The slide holder was rotated at least 90 degrees while being observed to detect any light 
refractions.  Images were taken by an Infinity CMOS camera. 
2.3.5 Size Exclusion Chromatography (SEC) 
Molecular weights of PVAL in both processed and unprocessed samples were 
analyzed with a Dionex Ultimate 3000 H/UPLC system equipped with a Shodex (Showa 
Denko K.K., Japan) Refractive Index detector.  Two Shodex Asahipak 7.6mm x 300mm 
(GF-7M HQ) columns were placed series and maintained at 40 °C.  A 50nM LiCl aqueous 
solution was utilized at the mobile phase at a constant flow rate of 0.7 mL/min.  Sample 
injection volumes were 100 µL [131]. 
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2.3.6 Non-sink Dissolution Analysis 
Non-sink dissolution analysis was conducted with a VK 7000 dissolution tester 
(Varian, Inc., Palo Alto, CA, USA) in accordance with USP XXXIV Method A for delayed 
release dosage form.  Solid dispersions (n=3) were weighed to achieve an equivalent of 
37.5 mg ITZ and placed in dissolution vessels containing 750 ml of 0.1 N HCl (~10x ITZ 
equilibrium solubility in acid) equilibrated to a temperature of 37.0 ± 1 °C with a paddle 
rotation of 50 rpm.  After 2 hours, a buffer medium of 250 mL of 0.2M Na3PO4, preheated 
to 37.0 ± 1 °C, was added to the dissolution vessels to adjust the pH to 6.80 and reach 1000 
mL in volume.  Samples were taken at 1, 2, 2.25, 2.5, 3, 4 and 5 hours.  Samples were 
immediately filtered using 0.2 µm PTFE membrane, 13 mm filters, diluted to a 1:1 ratio 
with mobile phase, mixed and then transferred into 1 mL vials for HPLC analysis. 
2.3.7 High Performance Liquid Chromatography 
The ITZ content in processed samples and dissolution aliquots were analyzed with 
a Dionex Ultimate 3000 H/UPLC system equipped with diode array detector extracting at 
263 nm.  The system was operated under isocratic conditions with a 70:30:0.05 
acetonitrile:water:diethanolamine mobile phase equipped with a Phenomenex Luna 5 µm 
C18(2) 100 Å, 150 mm x 4.6 mm (Phenomenex, Torrance, CA) HPLC column.  Dionex 
Chromeleon 7.2 software was used to analyze all chromatography data. 
2.3.8 In Vivo Studies 
In vivo studies were conducted at Charles River Laboratories (Wilmington, 
Massachusetts Facility) under NIH guidelines with IACUC approval.  Male Sprague-
Dawley rats equipped with a surgically-implanted jugular vein catheters to facilitate blood 
collection were prepared for the study.  Animals were assigned to the study based on 
catheter patency and acceptable health as determined by a staff veterinarian and placed into 
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groups of four animals (See Table 2.2 for details).  All animals were fasted overnight prior 
to dose administration and food was returned following the 4-hour post-dose blood 
collection.  All dosage forms were milled to a fine powder and suspended in an aqueous 
dosing vehicle to insure accurate ITZ to rat body weight medicating. 
Group 
No. 
No. of 
Males 
Treatment 
Test Article 
Dose Level 
 (mg API/kg) 
Dose Conc. 
(mg API/mL) 
Dose  
Volume 
(mL/kg) 
Dose Vehicle 
Dose 
Route 
1 4 
KSD 
[ITZ:PVAL 4-88 (1:4)] 
30 6 5 2% HPC/  
0.1% Tween 80/  
pH 2.0 
Oral 
gavage 
2 4 
Onmel™ tablets 
(pulverized) 
30 6 5 
Table 2.2: Rat PK study design 
Blood samples (0.25 mL; sodium heparin anticoagulant) were collected from the 
jugular vein catheter or by venipuncture of a tail vein if the catheter became blocked. Blood 
samples were collected from each animal at 2, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours following 
oral dosing. All whole blood samples were placed on wet ice immediately after collection 
and were centrifuged at 2-8ºC to isolate plasma. The resulting plasma was transferred to 
individual polypropylene tubes and immediately placed on dry ice until storage at 
nominally -20C before transfer to the Charles River’s Bioanalytical Chemistry 
Department for concentration analysis. 
Plasma samples were analyzed for itraconazole concentration using a proprietary 
in-house research grade LC-MS/MS Assay. Pharmacokinetic parameters were estimated 
from the plasma concentration-time data using standard noncompartmental methods and 
utilizing suitable analysis software (Watson 7.2 Bioanalytical LIMS, Thermo Electron 
Corp).  
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2.4 RESULTS AND DISCUSSION 
2.4.1 Preliminary Evaluation of PVAL Molecular Weight 
Due to the uniqueness of the KinetiSol® technology, screening methods do not exist 
to determine the processability of a new polymer.  So, three viscosity grades representing 
a low (PVAL 4-88), medium (PVAL 26-88) and high (PVAL 40-88) with the same level 
of hydrolysis were selected with an arbitrary ITZ loading of 20%.  Because of the feasibility 
nature of this study, KSD processing parameters were not optimized but considered 
acceptable if ITZ was rendered amorphous as determined by XRD and PLM analysis and 
drug assays were at least 96%.  This was easily achieved for the 4-88 grade as the 
discharged material was a single agglomerated, semi-molten mass similar in character to 
other previously processed formulations.  The 26-88 and 40-88 grades behaved differently 
in that the discharged material was a slightly densified powder.  Variance in processing 
RPM or increases in discharge temperature would not render an agglomerated discharge 
which is typical of the KSD processes (preliminary results not reported).  Other polymers 
with larger molecular weights have been used in previous research without incident [132].  
Thus, this phenomena must be attributed to the specific sintering properties or crystalline 
nature of high viscosity grades of PVAL.  The addition of 4-88 to 26-88 as a minor 
component allowed for an agglomerated discharge, however a 1:1 ratio of 4-88 to 40-88 
was required to achieve the same result.  For consistency, a 1:1 ratio of 4-88 to both 26-88 
and 40-88 was chosen as the compositions to continue this portion of the study. 
Size exclusion chromatography was performed on unprocessed polymer grades as 
controls and on the KSD processed compositions of ITZ with 4-88, 4-88:26-88 and 4-
88:40-88. Comparison of unprocessed and KSD processed 4-88 is shown in Figure 2.1A 
while comparison of unprocessed, one-to-one physical mixture of 4-88 and 40-88 to the 
KSD process composition is shown in Figure 2.1B. 
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Figure 2.1: SEC profiles of unprocessed powders and processed compositions. 
Peaks associated with polymer have been numbered, followed by the elution time 
(longer elution times signifies a smaller molecular weight).  Each sample was analyzed in 
triplicate, and representative chromatograms are presented herein.  Unprocessed 4-88 had 
a peak elution time of 24.917 minutes compared to the KSD processed 4-88 with a peak 
time of 24.638.  The physical mixture of 4-88 and 40-88 exhibited a first polymer peak at 
21.193 minutes, which corresponds with the 40-88 grade, and the second peak at 24.788, 
which is associated with the 4-88. The KSD composition showed elution times of the 
respective peaks at 21.103 and 24.407.  The small difference in the times can be explained 
by sampling variance and it can be concluded that KSD processing did not change the 
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molecular weight of PVAL.  However, it was noted that the KSD compositions always 
eluded at an earlier time compared to the corresponding unprocessed powder, which would 
indicate a slight increase in molecular weight.  It is plausible that a portion of the 
solubilized ITZ remains bound on the polymer following dissolution of the sample in the 
diluent and while traversing the column, which would increase the apparent size of the 
polymer coil and manifest as an increase in molecular weight.  The key result of this 
analysis is that there is no indication of a reduction in the molecular weight of the starting 
PVAL material after KSD processing.  
Dissolution profiles of the three compositions were compared (data not shown).  
The ITZ:4-88 and ITZ:4-88:26-88 compositions performed similarly, but the ITZ:4-88:40-
88 composition did not maintain ITZ supersaturation to the same extent following the pH 
change.  With its ease of processing and good dissolution profile, the 4 mPa·s grade of 
PVAL was selected as the molecular weight to continue evaluation of the effect of degree 
of hydrolysis on polymer performance. 
2.4.2 Solid-state Analysis 
Various hydrolysis grades of the same viscosity were selected for comparison with 
4-88, namely 4-38, 4-75 and 4-98.  Polyvinyl alcohol is known to be a crystalline polymer 
and XRD profiles were generated for each polymer used in this study to determine the 
effect of molecular weight and degree of hydrolysis has on the crystallinity (see Figure 
2.2).  The XRD data matches the reported information in that crystallinity does appear to 
increase with degree of hydrolysis.  The 4-38 grade, contains a greater component of 
polyvinyl acetate than PVAL, is the only grade that is XRD amorphous.  All the other 
grades had a primary peak between 19 and 20 2-theta with two other easily distinguishable 
peaks between 22 and 23 and between 40 and 42 2-theta.  The 26-88 and 40-88 grades 
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showed larger peak intensities than the 4-88 grade that might indicate increased 
crystallinity with molecular weight and would explain why these grades were more 
difficult to process at the selected conditions.  The 4-98 grade, which is the only fully 
hydrolyzed grade, demonstrated the highest peak intensities of all the grades tested. 
 
 
 
 
 
 
 
 
Figure 2.2: XRD profiles of PVAL grades used in study 
XRD profiles were also generated for ITZ and the processed compositions as 
illustrated in Figure 2.3. 
 
 
 
 
 
 
 
 
Figure 2.3: XRD profiles of ITZ and KSD compositions 
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For the 4-38, 4-75, 4-88 and 4-98 compositions, the profile demonstrates that the 
drug substance is amorphous while the polymers retain their crystalline structure.  In the 
compositions with a one to one polymer ratio of low molecular weight with higher 
molecular weight (only the 4-88:40-88 profile is shown, but the 4-88:26-88 profile was 
identical), the major crystalline peak is visible, but with lower intensity.  Other peaks are 
barely distinguishable.  It appears that the combination of different molecular weights 
interact in such a way as to reduce the crystalline structure of the polymer portion of the 
composite. 
mDSC analysis was conducted on the pure PVAL polymers to understand the 
thermal characteristic of each grade prior to analyzing the ITZ:PVAL KSD compositions.  
Considering that PVAL is a copolymer of polyvinyl acetate (PVAC) and PVAL one would 
expect to see by DSC analysis a Tg of the PVAC component and a melting endotherm of 
the crystalline PVAL component, the prominence of both being a function of the degree of 
hydrolysis.  That is to say that with increasing degree of hydrolysis, the Tg of the PVAC 
component will be less pronounced and the melting endotherm of PVAL will be more 
distinct.  Thus, a fully hydrolyzed grade would exhibit essentially no Tg associated with 
PVAC and a strong melting endotherm associated with PVAL.  The DSC thermograms for 
the four 4 mPa·s grades of PVAL and their corresponding KSD compositions provided in 
Figure 2.4 (nonreversing heat flow) and Figure 2.5 (reversing heat flow) demonstrate this 
expected trend. 
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Figure 2.4: Nonreversing Heat Flow DSC thermograms for 4 mPa·s grades of PVAL 
 
 
 
 
 
 
 
Figure 2.5: Reversing Heat Flow DSC thermograms for 4 mPa·s grades of PVAL 
It is seen that the 4-38 grade, which is predominantly PVAC, exhibits a strong Tg 
associated with the PVAC component and no detectable melting endotherm for PVAL 
[133].  The amorphous nature of this grade as demonstrated by DSC is in agreement with 
the previously discussed XRD result.  Hence, it is understood that below a critical degree 
of hydrolysis the PVAL component is unable to interact with itself to form crystallite 
structures due to the density of PVAC on the polymer chain.  Examining the thermograms 
for the 4-75 and the 4-88 grades, the expected trend is seen in that the Tg becomes less 
noticeable and the melting endotherm becomes more pronounced with an increased Tm as 
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the degree of hydrolysis is increased: consistent with increasing crystalline content of the 
polymer. The thermal profile obtained for the 4-98 grade matches industry literature for 
fully hydrolyzed polyvinyl alcohol with a melting point around 223 °C.  The reversing heat 
flow profile for PVAL 4-98 shows a slight thermal event around 70 °C which others have 
suggested was the Tg [134].  This event was much less prominent than the Tg events for 4-
88, 4-75 and 4-38 as would be expected considering the low PVAC content and was not 
able to be accurately quantified by the analysis software.  The DSC profile for the 4-98 
grade corroborates the XRD result indicating high crystallinity of the fully hydrolyzed 
grade. 
mDSC analysis was performed on the ITZ:PVAL KSD compositions to investigate 
the dispersed state of ITZ in each polymer grade and to evaluate the influence of the 
dispersed drug on the thermal properties of the polymers.  Figure 2.6 contains the 
nonreversing heat flow thermograms for the KSD composition and ITZ while Figure 2.7 
contains the reversing heat flow thermograms. 
 
 
 
 
 
 
 
Figure 2.6: Nonreversing Heat Flow DSC thermograms for KSD compositions and ITZ 
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Figure 2.7: Reversing Heat Flow DSC thermograms for KSD compositions and ITZ 
The nonreversing heat flow thermogram in Figure 2.6 shows a general trend of 
broadening and/or reduction in the magnitude of the glass transition event for the 4-38, 4-
75 and 4-88 grades relative to the pure polymers.  This could be attributed to dilution and/or 
anti-plasticizing effect of the dispersed ITZ phase.  Consistent with the pure polymer, a Tg 
is not apparent for the KSD composition with the 4-98 grade. Also seen for each of the 4-
38, 4-75 and 4-88 grades is an exothermic event indicative of ITZ crystallization with peak 
temperatures in the range of 117 – 127 °C.  Interestingly, the magnitude of the exothermic 
event is inversely proportional to the degree of hydrolysis.  This suggest that the physical 
stability of an ITZ amorphous dispersion in PVAL increases with increasing degree of 
hydrolysis.  One possible explanation for this is that increasing the degree of hydrolysis 
increases the density of hydrogen bon donor sites on the polymer backbone that could 
interact with the hydrogen bond acceptor sites on ITZ to form a stable complex [86].  
Another possible explanation is that the amphiphilic character of the polymer that stems 
from the ratio of hydrophilic PVAL-to-hydrophobic PVAC units approaches an optimum 
with regard to stabilizing interactions with ITZ as the percent hydrolysis is increased up to 
88%. 
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When the degree of hydrolysis is low, as with the 4-38 grade, the dispersed ITZ 
phase would interact largely with the PVAC component which contains only hydrogen 
bond acceptor sites (assuming hydrogen bonding is forming the complex).  Therefore, in 
this phase, the amorphous dispersion is stabilized by weaker intermolecular forces like Van 
der Waals forces.  If the stable complex is formed by hydrophilic/hydrophobic 
microenvironments, then the fewer hydroxyl groups of the 4-38 grade would provide fewer 
areas for interaction.  In either case, these weaker intermolecular forces are more easily 
disrupted by thermal perturbations; hence, post-Tg phase separation of amorphous ITZ and 
subsequent crystallization during the temperature ramp is observed to a greater extent with 
reduced degree of hydrolysis [135].  This is corroborated by the result for the fully 
hydrolyzed grade in which a crystallization exotherm was not detected.  
Figure 2.6 also shows that for all KSD processed compositions, a minor ITZ 
endotherm was detected.  For the KSD compositions with PVAL 4-38, 4-75 and 4-88, this 
endotherm is similar in magnitude to the crystallization exotherm, which suggest that the 
ITZ melting event is related entirely to ITZ that crystallized during the DSC scan.  This 
result validates the findings of XRD in which no crystalline ITZ was detected.  In the case 
of the 4-98 grade, where no crystallization exotherm was detected, the ITZ melting 
endotherm is likely due to residual crystalline ITZ remaining after processing.  This could 
be due to incomplete dispersion of ITZ in the polymer on processing resulting from the 
highly crystalline nature and/or the high Tm of the PVAL 4-98 grade.  It could also be the 
result of amorphous ITZ being forced out of its interaction with the polymer as the highly 
crystalline grade returned to its preferred crystalline orientation on quenching.  This result 
appears to contradict the XRD analysis; however, considering its small magnitude, the 
melting endotherm represents a small fraction of the dispersed ITZ, the crystalline peaks 
of which could be easily masked by the high intensity peaks of PVAL 4-98. 
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Finally, it is interesting to note in Figure 2.6 the melting endotherms for the PVAL 
4-75 and 4-88 are significantly reduced in comparison to the pure polymer; beyond what 
would be expected for a 20% dilution on the addition of ITZ.  This suggests that the 
dispersed ITZ phase disrupts crystallization of PVAL upon cooling due to drug/polymer 
interactions.  A similar melting endotherm, in terms of magnitude, between the pure 
polymer and the KSD composition for the 4-98 grade seems to suggest incomplete 
disruption of polymer crystallinity on processing and/or displacement of ITZ during the 
quenching process.  Considering this, it seems that a sufficient fraction of PVAC on the 
polymer is required to disrupt PVAL crystallite structure to facilitate a molten transition 
by KSD processing and achieve a homogenous dispersion of the drug substance [136].  
Additionally, PVAC units interspersed on the polymer backbone may act as defects within 
the PVAL crystallite structure that effectively make available sites for drug/polymer 
interactions [97].  However, one would expect to see a point of diminishing returns for 
increasing PVAC concentration as this would also lead to weaker drug/polymer 
interactions.  From Figure 2.6, it would appear that this optimum PVAL:PVAC ratio for 
ITZ is near that of the 4-88 grade. 
The reversing heat flow shown in Figure 2.7 shows similar trends to those of the 
nonreversing heat flow analysis, however with better resolution of the glass transition 
events.  Specifically, the Tgs of the KSD compositions with the 4-88 and 4-98 grades are 
able to be resolved by reversing heat flow analysis and have respective midpoint values of 
58.05 °C and 51.78 °C.  Also provided in Figure 2.7 is a thermogram for pure amorphous 
ITZ which shows a Tg of 59 °C followed by two endothermic events at 74 °C and 90 °C 
that have been identified as mesophases of glassy itraconazole [137].  In comparing all of 
the KSD compositions in the figure, the 4-88 grade has the highest composite Tg.  The Tg 
is more than 10 °C higher (roughly 20%) than KSD compositions with 4-38 and 4-75 
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grades as well as the pure 4-88 polymer and is close to the Tg of pure amorphous 
itraconazole.  The anti-plasticizing effect of amorphous ITZ on the 4-88 grade indicates 
strong positive drug-polymer interactions [138]; most likely due to hydrogen bonding 
between the acceptor sites on ITZ and the donor sites on PVAL.  The increased Tg relative 
to the other PVAL grades seems to also support the previously discussed hypothesis 
regarding an optimal ratio of PVAC to PVAL at which hydrogen bonding or 
hydrophilic/hydrophobic locations are maximized. From these results, it can be concluded 
that 4-88 is the best performer of the PVAL grades tested from a thermodynamic 
standpoint.   
2.4.3 Non-sink, Gastric Transfer Dissolution Analysis 
As discussed previously, PVAL is an interesting new carrier polymer in the area of 
supersaturating amorphous solid dispersions owing to its non-ionic nature and the high 
density of hydrogen bond donor sites on the polymer chain.  These attributes make it a 
particularly attractive concentration enhancing carrier for weakly basic drugs which have 
been shown to interact strongly with anionic carrier polymers to yield substantial 
improvements in apparent solubility [40].  To investigate the concentration enhancing 
effects of PVAL on ITZ, the dissolution properties of the four KSD compositions were 
evaluated by a non-sink, gastric transfer dissolution method. The results of this analysis 
are presented in Figures 2.8 and 2.9. 
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Figure 2.8: Dissolution Profiles for 4 mPa·s grades KSD compositions 
 
 
 
 
 
 
 
 
 
Figure 2.9: Dissolution Profiles for 4 mPa·s grades KSD compositions presented as 
concentration (C) relative to the saturation concentration (Cs) of ITZ at the 
respective pH. 
Both the 4-75 and 4-88 compositions achieved complete drug dissolution before 
the pH change at 2 hours, while the 4-38 and 4-98 grades did not.  Polyvinyl acetate is not 
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water soluble, which would explain why 4-38 did not go into solution like the higher 
hydrolyzed grades.  Owing to its highly crystalline nature, the 4-98 grade dissolves at a 
very slow rate under the dissolution conditions of this study; hence, ITZ release from this 
composition is slow and incomplete.  After the pH change, the 4-88 grade provided 
superior concentration enhancing effect presumably due to the greater PVAL content on 
the polymer and increased probability of ITZ interaction with the polymer in solution.  The 
4-38 and the 4-98 grades provided essentially no concentration enhancing effect due to the 
low concentration of dissolved polymer in the dissolution medium.  Contrasting the 
dissolution AUCs after the pH change, gives a rank order of 4-88 > 4-75 > 4-98 > 4-38 
with respective values of 640 ± 89, 442 ± 23, 130 ± 9 and 115 ± 8 mg·min.  By way of 
comparison, DiNunzio et al. reported a post pH change dissolution AUC for Sporanox® 
capsules of 226 ± 23 mg·min [42].  In Figure 2.9, these dissolution results are presented in 
terms of concentration at each time point (C) relative to the saturation concentration (CS) 
of ITZ at the respective pH. It should be noted that the CS for ITZ decreases dramatically 
from 5 µg/ml to 1 ng/mL when the pH of the media is changed from 1.2 to 6.8 [5]. When 
plotted in this manner, the extent of supersaturation enabled by PVAL 4-88 at neutral pH 
becomes quite evident with solution concentrations nearly 9,000 times the saturation 
concentration of ITZ. These results therefore demonstrate that PVAL is an effective 
concentration enhancing polymer for ITZ and support the hypothesis that hydrogen bond 
donor sites are the key points of interaction with weakly basic compounds that provide 
stabilization/prolongation of aqueous supersaturation. 
2.4.4 In Vivo Study 
From solid state and dissolution evaluation of PVAL grades with varying degrees 
of hydrolysis, PVAL 4-88 emerged as the top performing polymer.  In order to investigate 
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the effect of this polymer on the oral absorption of ITZ from an amorphous dispersion, the 
pharmacokinetics (PK) following oral administration to a rat model of this binary 
composition were comparatively evaluated against the commercially available ITZ 
product, Onmel™. The plasma concentration versus time profiles generated from this study 
are shown in Figure 2.10 while the key pharmacokinetic parameters as calculated by non-
compartmental analysis are provided in Table 2.3 with the addition of previously obtained 
results for Sporanox®.  Table 2.3 contains the plasma drug concentration AUC(0-last), AUC(0-
∞ ), Cmax and Tmax. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Rat PK of PVAL 4-88 compositions compared with Onmel™. 
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 AUC(0-last) 
(hr·ng/mL) 
AUC(0-∞) 
(hr·ng/mL) 
Cmax 
(ng/mL) 
Tmax 
(hr) 
ITZ:PVAL 4-88 (1:4) 3,315 ± 1336 3,595 ± 1662 391 ± 111 3.88 ± 0.25 
Onmel™ 2,565 ± 1374 2,624 ± 1391 367 ± 202 3.50 ± 1.22 
Sporanox® (From 
[42]) 
2,132 ± 1273  359 ± 261 5.5 ± 2.3 
Table 2.3: Rat PK mean calculations 
The mean AUC and Cmax for the PVAL 4-88 composition was greater than that of 
Onmel™ and Sporanox®.  However, it is noted that the drug loading of the ITZ:HPMC 
dispersion in the Onmel™ tablet is double that of the PVAL 4-88 composition.  Similarly, 
the nonpareil beads in the Sporanox® composition are coated with a 40% w/w itraconazole 
and 60% w/w HPMC solid dispersion [139]. Therefore, the contrast with commercial 
products is not a true apple-to-apple comparison.  Further studies will evaluate PVAL 
compositions at 40% w/w loading to have a more comparable result. Yet, considering the 
exploratory nature of this study, the analogous in-vivo performance of this first generation 
PVAL composition to commercial products is noteworthy.  
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2.5 CONCLUSION 
This feasibility study has demonstrated that PVAL’s pH independent solubility 
along with tunable density of functional groups allow it to function as a concentration 
enhancing polymer, effectively increasing the apparent solubility of poorly water soluble 
drug, itraconazole. The KinetiSol® technology enables the use of PVAL as the primary 
carrier for amorphous solid dispersion compositions. Solid-state and non-sink dissolution 
analysis revealed that the 88% hydrolyzed grade of PVAL was optimal for the ITZ 
compositions. Pharmacokinetic analysis in a rat model demonstrated that the ITZ/PVAL 
4-88 composition yielded exposures that were possibly superior to Sporanox® and 
Onmel™. 
Future research with ITZ will evaluate the effect of molecular weight in the range 
between the 4-88 and 26-88 PVAL grades tested in this study on dissolution performance.  
It will also explore increased drug loading levels, and evaluate storage stability.  Additional 
separate studies are planned to determine the broad application of PVAL evaluating 
amorphous dispersions with neutral and weakly acidic drug substances.  This 
supplementary information would offer a foundation for development scientists, who are 
looking for new options in formulating challenging drug substances, to have confidence in 
exploring polyvinyl alcohol. 
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Chapter 3 
New Use of Polyvinyl Alcohol as a Solubility Enhancing Polymer for 
Poorly Water-soluble Drug Delivery (Part 2) 
3.1 INTRODUCTION 
One of the current challenges facing the pharmaceutical industry is addressing the 
increasing presence of poorly water soluble drugs in commercial products and development 
pipelines [2-4].  Using amorphous solid dispersions for oral delivery as a method to solve 
these challenges has increased in popularity in both commercial products and industry 
literature [1, 140-142].  For research purposes, itraconazole is often used as a model drug 
for concentration enhancement due to its aqueous solubility of approximately 1 ng/ml at 
neutral pH and approximately 4 µg/ml at 1.2 pH [41, 143, 144].  ITZ has been formulated 
in various polymeric carriers including hydroxypropylmethylcellulose (HPMC) [87, 89], 
copovidone (PVPVA) [94], polyethyleneglycols (PEG) [97], polymethacrylates [145], 
hypromellose acetate succinate (HPMCAS) [146], hypromellose phthalate (HPMCP) [41], 
Soluplus® [147], polyvinyl acetate phthalate (PVAP) and cellulose acetate phthalate (CAP) 
[42]. 
The KinetiSol® Dispersing (KSD) technology is a thermal process than can create 
solid amorphous systems from challenging drugs and very highly viscous polymers [71].  
Utilizing this technology in our previous study, a broad range of molecular weights and 
degrees of hydrolysis of polyvinyl alcohol (PVAL) were investigated as a primary carrier 
in amorphous solid dispersion systems and for their solubility/bioavailability enhancing 
effect on itraconazole.  EMD Millipore’s PVAL was utilized in both studies and the 
nomenclature for describing different polymer grades is X-Y.  X represents the viscosity 
(in mPa·s) of the 4% aqueous solution at 20 °C, which is a relative indication of the molar 
mass and Y is the degree of hydrolysis of the polyvinyl acetate.  An examination of the 
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effects of molecular weight were conducted using PVAL 4-88, 26-88 and 40-88 with the 
4-88 grade performing the best both from a KinetiSol® processing and dissolution 
enhancement point of view.  Subsequently, 4-38, 4-75, 4-88 and 4-98 grades of PVAL 
were tested to ascertain the effect of the degree of hydrolysis for dissolution performance 
of ITZ.  PVAL 4-38 did not fully release due to the fact that polyvinyl acetate, the 
predominant component of the grade, is less water soluble than PVAL.  PVAL 4-98 also 
did not fully release due to the highly crystalline nature of the fully hydrolyzed grade which 
swelled in the aqueous environment, but did not completely dissolve.  Both PVAL 4-75 
and 4-88 released fully in the acidic portion of the dissolution test, but after the pH change 
to the neutral media the 4-88 grade provided best maintenance of supersaturated drug 
concentrations. 
Research conducted on various molecular weights of HPMC on the dissolution 
performance of ITZ show that higher molecular weights are more efficient stabilizers of 
drug supersaturation after the pH change from the acidic gastric condition to the neutral 
intestinal environment [41, 132].  Similar to HPMC, PVAL has a wide spectrum of 
molecular mass from low to high viscosity ranges and it is anticipated that it will have an 
effect on the performance of the amorphous dispersion.  Previous experimentation of 
PVAL 26-88 and 40-88 showed that these grades are excessively viscous as to pose 
processing challenges, which resulted in uneven drug distribution within the polymer.  
However, there are several grades between 4-88 and 26-88, namely 5-88, 8-88, 18-88 and 
23-88, which could be investigated to determine if molecular weight effects post pH change 
dissolution performance.  The current research comparatively evaluated the PVAL grades 
within a processable viscosity range (4-88 to 18-88) for their effect on the properties of 
amorphous dispersions of ITZ prepared by KSD. 
 73 
Rendering a drug amorphous within a semi-crystalline polymeric carrier does raise 
concerns for the long term storage stability of the formulation [148-150].  Since the drug 
thermodynamically prefers the crystalline state, the polymeric carrier must prevent this 
occurrence through steric hindrance or molecular interaction.  The concern of semi-
crystalline polymers is that structured molecular geometry either allows for the formation 
of polymer rich and drug rich domains or that the crystalline geometry negatively 
influences the unstable amorphous drug.  This is due to the stronger polymer-polymer 
interactions with semi-crystalline polymers (compared to amorphous ones) and hence the 
drug must compete with the polymer itself for binding sites on the formation and on the 
storage of the dispersion.  PVAL does have at least one advantage over other semi-
crystalline polymers like polyethylene glycol (PEG) in that it does have a higher Tg and 
Tm, which results in lower molecular mobility at temperature ranges associated with 
physical stability. 
PVAL is known for providing solution stabilization as it is used in the 
pharmaceutical industry both as a stabilizing agent for emulsions [110] and as an emulsifier 
in creating PLGA nanoparticles [117, 118].  The previous research illustrated in both in 
vivo and in vitro studies PVAL’s ability to increase free drug concentrations, and 
consequently oral absorption of the small molecule, itraconazole.  Because of this 
performance, it is hypothesized that an in solution interaction exists between ITZ and 
PVAL and can be characterized. In an attempt to determine the mechanism of interaction 
that allows this apparent solubility increase, the current study employed the analytical tools 
of Fourier transform infrared spectroscopy (FTIR) and dissolution-ordered spectroscopy 
(DOSY).  
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3.2 MATERIALS 
Itraconazole was purchased from Neuland Laboratories Limited (India).  All grades 
of PVAL (EMD Millipore) were donated by Merck Millipore.  All other chemicals used in 
this study were ACS grade 
3.3 METHODS 
3.3.1 KinetiSol® Dispersing (KSD) 
Compositions for this study were produced by a lab scale, GMP pharmaceutical 
compounder designed and manufactured by DisperSol Technologies, L.L.C. (Georgetown, 
TX, USA).  Prior to KSD processing, materials were weighed, dispensed into a 
polyethylene bag, manually shaken for approximately 1 minute, and charged into the 
compounder chamber.  During processing, computer controls monitor processing 
parameters in real time and eject the material at a pre-set ejection temperature.  Discharged 
material was immediately quenched in a cooling die under pressure in a pneumatic press.  
Cooled material was then cryomilled in a SPEX 6870 Freezer/Mill, with a 2 cycle run of 5 
minutes each at 10 cycles per second after a 3 minute cool time and 2 minute timer between 
cycles.  All further analyses was conducted on this powder. 
3.3.2 Powder X-Ray Diffraction (XRD) 
An Inel Equinox 100 X-ray diffractometer (INEL, Artenay, France) was used to 
detect the presence of ITZ crystallinity.  Milled compositions, physical mixtures and 
unprocessed, pure ITZ were individually loaded on a rotating aluminum sample holder and 
placed in the radiation chamber.  The Equinox 100 utilizes Cu K Alpha radiation (λ = 
1.5418 Å) with a curved radius detector to simultaneously measure a 2ϴ range of 5 - 110°.  
Operating voltage and amperage were adjusted to 41 kV and 0.8 mA respectively and the 
scan time for each sample was 10 minutes. 
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3.3.3 Polarized Light Microscopy (PLM) 
PLM analysis was conducted on a Meiji Techno MT 9300 polarizing light 
microscope with a first order red compensator.  Pulverized samples were dusted on a glass 
slide and viewed under 400x magnification.  The slide holder was rotated at least 90 
degrees while being observed to detect any light refractions. 
3.3.4 High Performance Liquid Chromatography (HPLC) 
The ITZ content in processed samples and dissolution aliquots were analyzed with 
a Dionex Ultimate 3000 H/UPLC system equipped with diode array detector extracting at 
263 nm.  The system was operated under isocratic conditions with a 70:30:0.05 
acetonitrile:water:diethanolamine mobile phase at a flow rate of 1.0 mL/min.  The column 
used for analysis was a Phenomenex Luna 5 µm C18(2) 100 Å, 150 mm x 4.6 mm 
(Phenomenex, Torrance, CA, USA) HPLC column.  Dionex Chromeleon 7.2 software was 
used to analyze all chromatography data. 
3.3.5 Non-Sink Dissolution Analysis 
Non-sink dissolution analysis was conducted with a VK 7000 dissolution tester 
(Varian, Inc., Palo Alto, CA, USA) configured as Apparatus 2. The test was performed 
similar to USP XXXVII (38) dissolution for delayed release dosage forms.  Solid 
dispersions (n=3) were weighed to achieve a mass equivalent to 37.5 mg ITZ and dispensed 
in dissolution vessels on the surface of 750 ml of 0.1 N HCl (~10x ITZ equilibrium 
solubility in acid) equilibrated to a temperature of 37.0 ± 1 °C with a paddle rotation of 50 
rpm.  After 2 hours, a buffer medium of 250 mL of 0.2M Na3PO4, preheated to 37.0 ± 1 
°C, was added to the dissolution vessels to adjust the pH to 6.80. 
Drug content in solution was directly measured with a fiber optic Spectra™ 
instrument (Pion Inc., Billerica, MA, USA) fitted with 5 mm path length Pion Probes.  
 76 
Readings were recorded every 5 minutes over the entire duration.  Additionally, samples 
were taken at 2:00, 2:05, 2:10, 2:15, 2:30, 3:00, 3:30, 4:00 and 5:00 hours.  Samples were 
immediately filtered using 0.2 µm PVDF with GMF membrane, 13 mm filters, diluted at a 
1:1 ratio with mobile phase, mixed and then transferred into 1.5 mL vials for HPLC 
analysis.  Pion data was correlated to match HPLC results by selecting appropriate 2nd 
derivative parameters. 
3.3.6 Precipitation Inhibition Analysis 
Solid dispersions (n=3) were weighed to achieve an equivalent of 37.5 mg ITZ and 
placed in suitable vessels containing 750 ml of 0.1 N HCl (to match concentrations in non-
sink dissolution studies) that had been equilibrated to a temperature of 37.0 ± 1 °C.  
Containers were placed on stirring tables and agitated vigorously for several hours until 
solutions became clear.  Media was then transferred to dissolution vessels within a VK 
7000 dissolution tester (Varian, Inc., Palo Alto, CA, USA) configured as Apparatus 2 with 
a paddle rotation of 50 rpm.  A buffer medium of 250 mL of 0.2M Na3PO4, preheated to 
37.0 ± 1 °C, was added to the dissolution vessels to adjust the pH to 6.80.  Samples were 
taken immediately before pH change, then after the pH change at 5, 10, 15, 30, 60, 90, 120, 
and 180 minutes.  Samples were immediately filtered using 0.2 µm PVDF with GMF 
membrane, 13 mm filters, diluted to a 1:1 ratio with mobile phase, mixed and then 
transferred into 1.5 mL vials for HPLC analysis. 
3.3.7 Fourier Transform Infrared Spectroscopy (FTIR) 
Samples were tested in a Thermo Scientific Nicolet iS50 FT-IR Spectrometer 
(Thermo Electron Scientific Instruments LLC, Madison, WI, USA) with the Omni-
Sampler module for attenuated total reflectance (ATR).  The scan range was 2000 – 700 
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wavenumber (cm-1) at a resolution of 4 cm-1 for 32 scans per sample.  Data collection and 
analysis were performed with OMNIC™. 
3.3.8 Diffusion-Ordered Spectroscopy (DOSY) 
Amorphous dispersions and PVAL were dissolved in deuterated solutions of 0.1N 
DCl prepared by diluting concentrated DCL with D2O.  Samples were tested in a Varian 
VNMRS 600MHz nuclear magnetic resonance (NMR) spectrometer (Palo Alto, CA, USA) 
for solution with a Doneshot pulse sequence.  The spectra was adjusted until water at 25 
°C was 19.02 x 10-10 and all data generated is correlated to that reference.  Figures were 
generated using Varian VNMRJ software. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Evaluation of PVAL Molecular Weight 
To be consistent with our previous study, a drug loading of 20% ITZ was selected 
for the preparation of amorphous dispersions with PVAL grades of 4-88, 5-88, 8-88 and 
18-88.  All acceptable KSD compositions were verified to be amorphous by XRD and 
PLM, and HPLC analysis was conducted to establish dispersion potencies (data not 
shown).  For dissolution testing, the samples were weight adjusted according to potency to 
achieve an equivalent amount of ITZ in each vessel.  Figure 3.1 contains the dissolution 
curves of the listed PVAL grades for the 2 hour pH change dissolution method.  Error bars 
are not shown due to data density making them indistinguishable. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Dissolution profiles of 20% ITZ in PVAL 4-88, 5-88, 8-88 and 18-88. 
Both PVAL 4-88 and 5-88 grades fully released ITZ at supersaturated levels with 
little variance between the two in the acid phase.  PVAL 8-88 and 18-88 were not able to 
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achieve complete release, which was observed during the test with powder appearing at the 
bottom of the dissolution vessels after approximately an hour.  After the pH change the 
precipitation inhibition performance followed the reverse order of molecular weights: 4-88 
> 5-88 > 8-88 > 18-88. 
Prior to the pH change, 8-88 had only reached 70% of drug in solution and 18-88 
had only attained 60%.  It was speculated that if these two grades could achieve 100% drug 
release the rank order of performance might change.  An alternative dissolution study using 
the same amorphous dispersions, called precipitation inhibition analysis, was conducted 
which forced complete drug release from all polymer grades prior to the pH change with 
the results exhibited in Figure 3.2. 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Precipitation inhibition curves of 20% ITZ in PVAL 4-88, 5-88, 8-88 and 
18-88. 
Even with the formulations at the same starting point, the lower molecular weights 
outperformed the larger ones in reducing the rate of drug precipitation.  These results match 
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the previous study where PVAL 4-88 provided better performance than combinations 
containing the 26-88 and 40-88 grades.  Thus, contrary to the trends observed with HPMC, 
for PVAL the lower molecular weights have superior dissolution performance over higher 
molecular weights. 
This trend is confirmed by comparing the rates of dissolution for the polymers 
themselves in water.  Product literature shows that lower molecular weights of the -88 
grades have faster dissolution rates specifically in the temperature range between 20 and 
40 °C [109].  Additionally, as shown in that same product literature, PVAL reduces 
interfacial tension, particularly the surface tension of water with respect to air, with 
differing effects according to molecular weight as seen in Figure 24.  That figure 
specifically compares PVAL grades 40-88, 18-88, 8-88 and 4-88 for reduction in water 
surface tension.  The rank order of greatest surface tension reduction to lowest is 4-88 > 8-
88 > 18-88 > 40-88.  Thus, the lower molecular weights have a greater reduction in surface 
tension of water. 
Since amorphous dispersion powders were dispensed on the surface of the media 
in the vessels for the non-sink dissolution test, the lower surface tension and faster 
dissolution rate of the lower molecular weight grades would speak to the faster dissolution 
rate of ITZ.  The effect on water surface tension indicates that lower molecular weight 
grades effectively function as a polymeric surfactant more than higher molecular weights.  
This would support the results for the precipitation inhibition analysis where the lower 
molecular weights were more effective in reducing the rate of drug precipitation. 
3.4.2 Drug Loading Evaluation 
All dissolution studies from the current and previous research have been conducted 
with 20% drug loading.  It is noted that the drug loading of ITZ:HPMC in the commercial 
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product Onmel™ and the coating for the nonpareil beads in Sporanox® which is also ITZ 
in HPMC are both 40% [139].  Typically, the higher the drug load, the lower the dissolution 
performance because the ratio of drug to polymer decreases and solubility enhancement 
trends with increasing polymer concentration [151].  However, if higher drug loading can 
be achieved, the size of the dosage form can be reduced, typically improving patient 
convenience and compliance.  Hence, optimal drug loading is a balance between 
performance and size of the final dosage form. 
To investigate the effect of drug loading on dissolution performance, amorphous 
dispersions of ITZ in PVAL 4-88 were produced at 10, 20, 30, 40 and 50% drug loads.  
HPLC analysis measured actual potencies and samples were weight adjusted to ensure 37.5 
mg of drug were contained in each dissolution vessel.  The result from the non-sink 
dissolution test is found in Figure 3.3. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Dissolution comparison of different ITZ loadings in PVAL 4-88. 
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The rank order from highest dissolution performance in acid is as follows: 20% > 
30% > 40% > 10% > 50%.  Surprisingly, the 10% dispersion did not have the highest rate 
of dissolution.  It exhibited a faster initial rate than 30% and 40%, but slowed after the 
initial 20 minutes to perform only better than the 50% loading.  Only the 10% and 50% 
drug loading did not achieve 100% drug release within the two hour window of the acid 
portion of the experiment. 
Toward the end of the 2 hour acid phase of the dissolution test, powder was visible 
at the bottom of the vessel of the 50% composition.  All other vessels were clear at the 
bottom, however there was still powder floating at the top of the vessel of the 10% drug 
load sample.  Keeping the relative amounts in perspective can provide probable 
explanations for this behavior.  The 10% drug loading has a theoretical weight of 375 mg, 
the 20% drug loading has 187.5 mg weight on down to the 50% drug loading only having 
75 mg of total amorphous intermediate powder.  The 187.5 mg of 20% ITZ loaded powder 
floated on top (like all other samples) initially, then within a few minutes dispersed into 
the vessel and was dissolved within 20 minutes.  Both the 30% and 40% loaded samples 
followed the same pattern, but with longer timeframes.  In the case of the 10% ITZ 
dispersion, the time for the floating material to disperse within the aqueous environment 
and then dissolve was so prolonged that a very small amount of powder remained on the 
top surface at the end of the 2 hour acid phase.  Visually, it was only a fraction of the initial 
375 mg amount but it is unclear as to whether it could account for all of the undissolved 
amount of ITZ. 
Results from the previous study and product literature show that increasing polymer 
crystallinity reduces polymer solubility and dissolution rate.  The lowest drug loading at 
10% would have the highest allowance for the formation, in some regions, for the preferred 
crystalline configuration which would slow dissolution and negatively affect solubility.  
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With the more crystalline configuration, ITZ could be entombed in highly crystalline 
regions which would account for the incomplete release and the more sustained drug 
solubility after the pH change due to higher polymer concentrations.  Increasing drug load 
would decrease polymer crystallinity and allow for the faster dissolution for the 20% 
sample.  However, increasing the drug loading also increases the hydrophobicity of the 
dispersion resulting in slower wetting and dissolution as seen with the 30% and 40%.  The 
50% dispersion would have the lowest polymer crystallization, but also the most reduced 
wetting and diminished release rate due to low polymer concentration. 
After the pH change the rank order follows as was expected with 10% > 20% > 
30% > 40% > 50%.  10% ITZ did start at a lower concentration than the 20%, but had 
higher actual amounts of drug in solution at 180 minutes which was an hour after the pH 
change.  The 20% ITZ composition had the fastest dissolution rate and reduced the rate of 
precipitation at a similar level to the 10% composition.  The 30% loading was a close 
second to 20% in the acid phase dissolution and exhibited a rate of precipitation only 
slightly lower than both the 10% and 20% compositions.  Since, optimal drug loading is a 
balance between performance and size of the final dosage form, the 30% loading is 
probably closer to the optimal drug loading than all the other drug loadings tested. 
3.4.3 Evaluation of the ITZ/PVAL Interaction 
Because the ITZ is amorphous in the solid dispersion, it is not surprising to see 
apparent solubility levels much higher than the crystalline equilibrium solubility.  
However, without the aid of a solubility enhancing/stabilizing polymer, the 
thermodynamically unstable supersaturation would soon return to the crystalline 
equilibrium solubility.  Especially, as the aqueous environment transitions from the acid 
gastric environment to the pH neutral environment of the intestinal tract, a weakly basic 
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drug like ITZ would return to solubility equilibrium quite rapidly [132].  Dissolution 
profiles contained in this and the previous study report concentration levels as high as 8,000 
times the saturation concentration in neutral media and maintaining at least 4,000 times the 
saturation concentration for 30 minutes after the pH change.  These results suggest an 
attractive interaction between the ITZ and PVAL. 
FTIR-ATR has been reported as an analytical tool to investigate such possible 
interactions [53, 152, 153].  Peaks in the spectra can be associated with specific atomic 
bonding and shifting or changing shape can indicate molecular interactions.  Figure 3.4 
contains the FTIR spectra of amorphous itraconazole, preprocessed PVAL 4-88 and 
amorphous solid dispersions of 10% and 20% ITZ loading in PVAL 4-88. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: FTIR-ATR spectra of amorphous ITZ, PVAL 4-88, and amorphous 
dispersions. 
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The result for ITZ is similar to published literature [154, 155] and the PVAL result 
is consistent with product literature [109].  For PVAL, the broad peak at 3330 cm-1 is 
associated with O-H stretching, the small peak at 2941 cm-1 with C-H stretching, the 1732 
cm-1 peak with C=O groups (from unhydrolyzed ester groups), the peak at 1429 cm-1 with 
CH2 bending, the 1251 cm-1 peak with the C-O-C groups (also from unhydrolyzed ester 
groups) and, finally, the 1093 cm-1 peak is associated with C-O stretch and O-H bending.  
For ITZ, the first major peak at 1700 cm-1 is associated with C=O stretching, the 1511 cm-
1 peak is related with CO-NH2, and the 946 cm-1 linked with C-Cl.  Most peaks do not show 
any difference between the individual components and the amorphous dispersions.  Yet, 
the broad peak associated with O-H stretching on PVAL showed a shift from 3330 cm-1 to 
3334 and 3335 cm-1 on the 10% and 20% ITZ loading in PVAL 4-88 respectively.  The 
ITZ peak at 1700 cm-1 that correlates to C=O stretching, shows a change of 1713 and 1706 
cm-1 for the same respective 10% and 20% ITZ loaded amorphous dispersions.  As 
mentioned previously, the 10% amorphous dispersion will exhibit a higher degree of 
polymer crystal formation than the 20% load, which might explain the larger shift for the 
lower drug load.  While it does appear that hydrogen bonding might be occurring, the 
magnitude of the shifts advocates that interactions, more than just hydrogen bonding alone, 
would account for the storage stability of the amorphous dispersion.   
Diffusion-ordered spectroscopy (DOSY) or sometimes called diffusion-ordered 
NMR spectroscopy and diffusion-ordered correlation spectroscopy has been used to 
determine the drug complexation with cyclodextrins [156], drug release from a hydrogel 
matrix [157], identification of fake formulations of commercial products [158], and to see 
the interactions of polymers and drugs in solution [159].  DOSY is a measure of diffusion 
and can distinguish different components in a formulation by the rate of diffusion and 
location on the spectra.  Small molecules have a faster diffusion rate than large polymers 
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and will have a different measurement of diffusion unless they are strongly bound by a 
covalent, ionic or hydrogen bond, which would give them the same measurement of 
diffusion as they act as single entity.  Figure 3.5 has the DOSY map for PVAL 4-88 only 
and for the 20% drug loading in PVAL4-88. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: DOSY maps of (A) PVAL 4-88 and (B) 20% ITZ in PVAL 4-88 amorphous 
dispersion. 
The Y or F1 axis is the measurement of diffusion or how well the molecules travel 
within the solution with lower numbers at the top representing slower diffusion and 
increasing with the numbers to reach the highest diffusion rates at the bottom.  The X or 
F2 axis helps track any chemical shift from the top spectra.  Figure 3.5A is a map of pure 
PVAL 4-88 that has not been processed.  It is interesting to note that the polymer has two 
different diffusion coefficients, with the first band around 0.4 and the second one around 
A B 
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1.0 on the F1 axis.  Product literature speaks specifically about PVAL’s propensity toward 
complex formation in the presence of certain acids or salts [109].   Since the solution is 
0.1N DCl, it is possible to have PVAL form a bimolecular complex.  Additionally, in the 
discussion regarding PVAL reduction of water surface tension, it was mentioned that 
PVAL 4-88’s greater effect on surface tension would allow it to function with surfactant-
like properties, which would allow for molecules to self-associate in solution.  Thus, it 
appears that the two different diffusion coefficients is formed by some molecules going 
into solution in groups and other by themselves.  Whatever the actual cause is for the 
grouping phenomena, it appears that acetate groups on the PVAL molecular chain play a 
part because the spectra associated with acetate (around 2 on the F2 axis) is only observed 
in the slower diffusion group.  Also on Figure 3.5A is an area that is around 10 on the F1 
axis and around 2 on the F2 axis; this charts the residual acetyl groups within the bulk 
polymer. 
 Figure 3.5B is a map of the amorphous dispersion containing 20% ITZ in PVAL4-
88.  At the top, again, is the two different diffusion coefficients of the PVAL 4-88.  Around 
3 on the F1 axis is the spectra of itraconazole, which illustrates a different measurement of 
diffusion for the drug than the polymer.  This illustrates clearly that the drug is not tightly 
bound to the polymer by strong intermolecular interactions.  If there is any hydrogen 
bonding, the drug/polymer association would have to be flexible enough to allow ITZ 
movement along PVAL to account for the different rates of diffusion.  Ideally, a third 
DOSY map of only ITZ in solution would be very useful to see if the interaction of the 
polymer changes the diffusion for the drug to illustrate a practical interaction between the 
two, but, unfortunately, the concentration of ITZ in solution was below the limit of 
detection for this analytical test.  There is an area around 2 on the F1 axis that lies between 
the diffusion of PVAL 4-88 and ITZ that could possibly be a slower measured diffusion 
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for ITZ that would indicate an interaction.  However, it could also be a software 
interpretation error due to peaks of both PVAL 4-88 and ITZ both occurring in that area.  
Thus, the key conclusion that can be drawn from these results is that the concentration 
enhancing effect of PVAL on ITZ is likely the result of weak intermolecular interactions, 
such as van der Waals forces/hydrophobic interactions, as it appears that strong 
intermolecular interactions between ITZ and PVAL do not occur in solution.  This 
conclusion is supported by other research efforts that have looked at amorphous dispersions 
of ITZ with various polymeric carriers and concluded that hydrogen bonding was not the 
mechanism of action in solution between the drug and polymer [42, 132]. 
3.4.4 Evaluation of Stability 
One of the main concerns to be addressed when creating amorphous dispersions is 
the stability of the matrix to prevent the drug from returning to its crystalline state within 
the delivery form before dosage [54, 57, 160].  Physical stability of the drug substance can 
be achieved through kinetic stabilization or freezing the amorphous drug within the 
polymeric carrier.  This can be achieved by having a Tg of the composite matrix 50 °C 
above ambient storage conditions [52].  It can also be achieved by thermodynamic stability 
which is attained by molecular interactions that provide stability [56].  Many amorphous 
dispersions are formulated in a metastable region where the mode of stabilization is a 
combination of both kinetic and thermodynamic mechanisms [57].  Drug loading also 
influences stability because as loading is increased, at some point miscibility is exceeded 
and then drug molecule proximity within the polymer matrix becomes critical.  Stability 
tends to decrease because recrystallization becomes more probable as drug molecules are 
increasingly found in close proximately to other drug molecules. 
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The drug loading portion of the current study concluded that 30% ITZ in PVAL 4-
88 is probably closer to the optimal drug loading than all the other drug loadings tested.  A 
container (without desiccant) containing milled amorphous intermediate powder of 30% 
ITZ was stored at ambient conditions for 30 months.  A new sample that was identical in 
formulation was prepared and compared to the 30-month-old material by XRD and PLM.  
The XRD diffractogram is shown in Figure 3.6. 
 
 
 
 
 
 
 
 
 
Figure 3.6: XRD profiles of ITZ, initial and 30 month old amorphous dispersions. 
Both the initial and 30 month XRD profiles contain no peaks that correspond with 
ITZ indicating that both are substantially amorphous.  The major broad peak in the 
amorphous dispersions at approximately 19 2-theta and minor peaks at approximately 23 
and 41 2-theta are related to the crystallinity of the PVAL 4-88.  No visual crystal structures 
were observed in either samples by PLM.  Since it is possible to have crystals below the 
limit of detection of XRD and PLM, a dissolution study was conducted to confirm the 
dissolution performance of the amorphous compositions.  These results are presented in 
Figure 3.7.  As stated in the methods section, the first 120 minutes of the dissolution was 
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performed in 0.1 N HCL after which a buffer is added to change to a neutral pH.  Thus, in 
the acidic environment full release of ITZ is realized after which the pH change resulted in 
precipitation of ITZ.  Since only two dissolution profiles are compared in this figure, error 
bars were included to show the significance of any variation. 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: pH change dissolution comparing initial and 30 month ambient storage 
amorphous dispersions of ITZ:PVAL 4-88 (30% drug loading). 
The dissolution performance in 0.1 N HCl of the two compositions are comparable 
with the 30 month old composition performing slightly better.  Two different lots of PVAL 
4-88 were used to make these compositions, which could explain the slight variance.  
Another possibility is that the stored material had some water absorption that would allow 
for better wetting and faster release.  Since the purpose of the test was to determine crystal 
growth during storage, the reason for this variance was not investigated.  After the pH 
change, the two compositions performed similarly with the two curves staying within the 
error bars.  Because the dissolution performance is similar, it can be concluded that the 
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solid-state properties of ITZ in the PVAL matrix did not change during storage.  Therefore, 
dissolution performance and XRD results demonstrate acceptable real-time ambient 
stability for the lead ITZ:PVAL 4-88 composition. 
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3.5 CONCLUSION 
PVAL has been further investigated as a solubility enhancing polymer in 
amorphous solid dispersions as enabled by KinetiSol® Dispersing.  PVAL 4-88 was 
confirmed to provide the best solubility enhancement and in solution stability as compared 
with 5-88, 8-88 and 18-88 presenting a trend that lower molecular weights function better 
than higher molecular weight polyvinyl alcohols.  In a drug loading study, 20, 30 and 40% 
ITZ drug loads achieve full drug release in 0.1 N HCl in 2 hours, and were able to retard 
the return to the crystalline equilibrium solubility after the pH change in the expected rank 
order of 10%>20%>30%>40%>50% with the 30% loading selected as optimal.  DOSY 
and FTIR were used confirm that weak molecular interactions are the likely cause of solid 
state and solution stability of amorphous ITZ.  A 30 month stability study showed the 
optimal ITZ:PVAL 4-88 amorphous dispersion remained entirely amorphous as 
determined by XRD and PLM and the dissolution performance was unchanged. 
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Chapter 4 
Novel formulation approach for multiparticulate abuse deterrent 
development 
4.1 INTRODUCTION 
The misuse and abuse of prescription drugs poses a serious public threat in the 
United States today.  The Centers for Disease Control and Prevention (CDC) have declared 
that the United States is in the midst of an epidemic of prescription drug overdose deaths 
[161].  The CDC reported that drug overdose deaths were second only to motor vehicle 
crash deaths among the leading causes of unintentional injury death in 2007 [162].  That 
same report issued statistics that the number of deaths involving opioid analgesics was 1.93 
times the number involving cocaine and 5.38 times the number involving heroin.  A 2010 
Substance Abuse and Mental Health Services Administration survey found that 16 million 
Americans age 12 years and older had taken a prescription pain reliever, tranquilizer, 
stimulant, or sedative for nonmedical purposes at least once in the previous year; 7 million 
had used psychotherapeutic drugs nonmedically within the past month.  Of these drug 
abusers, 55% said they obtained the drug they most recently used from a friend or relative 
for free [163].  These statistics express the rising need for drug formulators and regulators 
to create barriers to prescription drug abuse. 
To combat this growing epidemic, the U.S. Food and Drug Administration has 
released a guidance document for drug formulation companies to follow for formulating 
prescription drugs prone to abuse [164].  That guidance document offers several suggested 
approaches that are summarized in Table 4.1. 
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Approach Brief Description 
Physical/chemical 
barriers 
Physical barriers can prevent chewing, crushing, cutting, 
grating or grinding of the dosage form.  Chemical barriers 
can resist extraction of the drug using common solvents like 
water or organic solvents. 
Agonist/antagonist 
combinations 
A drug antagonist can be added to interfere with, reduce or 
defeat the euphoria associated with abuse. 
Aversion Substances can be added to the product to produce an 
unpleasant effect if the dosage form is manipulated or is used 
at a higher dose than directed. 
Delivery system Certain drug release designs or method of delivery can offer 
resistance to abuse like a sustained-release subcutaneous 
implant. 
New molecular entities 
and Prodrugs 
The properties of a NME or prodrug could include the need 
for enzymatic activation, different receptor binding profiles, 
slower central nervous system penetration or other effects. 
Combination Two or more of the above methods could be combined to 
deter abuse. 
Novel approaches This category encompasses novel approaches that are not 
captured in the previous categories. 
Table 4.1: Categories for abuse deterrence as defined by the U.S. FDA. 
The first category, physical and chemical barriers, represent the most prevalent 
approach in currently available commercial products.  The most financially successful 
commercial abuse deterrent formulation has been Purdue Pharma’s OxyContin®, which 
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was reformulated in a polyethylene oxide matrix as a physical barrier and approved by the 
FDA in April 2010 [165, 166].  The original product label did not contain any information 
on abuse deterrence despite having in vitro evidence to support such a claim.  After product 
launch several studies investigated the public health impact of the OxyContin® 
reformulation to support the relabeling of the product with abuse deterrent information.  
One study looked at patients entering treatment programs with opioid dependency [167].  
The selection of OxyContin® as a primary drug of abuse decreased from 35.6% of 
respondents before the release of the abuse-deterrent formulation to just 12.8% 21 months 
later.  Those same respondents reported that of all opioids used to ‘get high in the past 30 
days’ OxyContin® fell about 40% while the use of heroin nearly doubled over the same 
time period.  Another study reported that abuse of the reformulated OxyContin® was 41% 
lower than historic abuse of the original formulation [168].  ‘Real world’ in vitro testing 
demonstrated the relative difficulty of manipulation of the reformulation [169] along with 
human in vivo testing [170] assessed the actual abuse deterrent properties of the 
reformulation.  While not completely tamper proof, the reformation of OxyContin® did 
prove to be a deterrent in all evaluations. 
The use of a polyethylene oxide (PEO) matrix has been utilized in Opana® (an 
oxymorphone reformulation by Endo Pharmaceuticals) and in Nucynta® (a tapentadol 
reformulation by Ortho-McNiell-Janssen Pharmaceuticals) but neither have been allowed 
to state abuse deterrence on product labels by the FDA even with some post-marketing 
studies [166].  Remoxy® (Pain Therapeutics, Inc.) is an oxycodone extended release 
product that does not use PEO to provide a physical barrier but rather a formulation 
containing sucrose acetate isobutyrate in a gelatin capsule [171].  The formulation creates 
a viscous mass that resists size reduction even when frozen and only releases a fraction of 
the oxycodone when submerged in high-proof alcohol for hours.  Clinical trials showed 
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significant pain reduction and survey data from drug counselors demonstrated that it was 
less preferred for abuse as compared to the original ER oxycodone formulation [172, 173].  
However, the FDA issued a complete response letter in June, 2011, indicating additional 
studies were required before approval would be granted.  Since sucrose acetate isobutyrate 
is not considered GRAS by the FDA, there appears to be an opportunity for creating a solid 
matrix product out of GRAS excipients that does not contain PEO as a barrier approach in 
abuse deterrent formulation. 
There are commercial products that belong to other abuse deterrent categories.  
Suboxone® is categorized as an agonist/antagonist combination of buprenorphine and 
naloxone, where the buprenorphine acts as a partial opioid agonist combined with the 
opioid agonist naloxone.  It was approved in 2003 by the FDA for the treatment of opioid 
dependence but is commonly used off-label as a pain therapeutic [174].  Embeda® is also 
an agonist/antagonist combination of morphine and naltrexone.  When taken orally as 
intended, the naltrexone is not released.  But, if the tablet is chewed or crushed prior to 
taken orally, the naltrexone is released with the morphine and the agonist activity is limited 
[175].  This complex formulation encountered manufacturing issues and was recalled in 
March, 2011.  Oxecta® is an immediate release formulation of oxycodone that contains 
aversive ingredients.  Since the active ingredient is readily available via the oral route, the 
aversion abuse deterrent approach is to reduce non-oral abuse.  The formulation contains 
sodium lauryl sulfate which irritates the nasal cavity to deter insufflation and it also 
contains excipients that form a gel when exposed to water to deter intravenous use [176]. 
 Dysphagia, or difficulty in swallowing tablets, greatly influences patient 
compliance.  A study has shown that up to ¼ of the general population may have problem 
swallowing, with the very young having the most difficulty followed by elderly patients 
[177].  Unfortunately, these age groups are commonly issued prescriptions for drugs that 
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are likely to be abused.  For example, in 2007, 3.1 million youths aged 12 to 17 received 
treatment or counseling for problems with behavior or emotions with a significant 
percentage receiving psychotherapeutic drugs [178].  On the other hand, different studies 
have shown that the age group most likely to suffer from chronic pain is age 50 to 64 [179, 
180].  It would be highly beneficial to have a delivery form that could simultaneously 
provide ease of dosing for patent compliance while at the same time delivering abuse 
deterrence. 
 One such approach would be to have a physical barrier formulation in a 
multiparticulate delivery form rather than a single, larger abuse deterrent tablet.  The 
smaller particles would allow for oral delivery by sprinkling onto soft food for consumption 
to help with patient who suffer with dysphagia.  In addition to ease of dosing, there are 
other biopharmaceutical advantages with having a multiparticulate delivery form.  
Gastrointestinal tract (GIT) transit time for small particles would not depend upon gastric 
emptying, which would result in a more uniform distribution in the GIT and less variable 
pharmacokinetic profiles among patients.  However, the challenge with a multiparticulate 
approach is that the smaller particle size has higher susceptibility to certain mechanical 
abuse techniques such as size reduction by a coffee grinder or mortar and pestle.  The high 
surface area also lends faster drug release when submerged in ethanol, which is also a 
common abuse technique.  So, while the theory of a multiparticulate delivery is appealing, 
the technical details to the approach are challenging. 
Currently, the most published multiparticulate approach is a platform technology 
called DETERx (Collegium Pharmaceuticals, Inc.) that creates a complex of drug with 
fatty acid and then places it with a hydrophobic waxy matrix in submillimeter, spherical 
particles for extended release [181-183].  The spherical particles are prepared using a 
standard spray congealing process and are specifically designed to retain the time-release 
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mechanism following common methods of tampering (e.g. crushing, chewing, heating for 
IV injection, etc.).  The release profile can be adjusted by excipient ratios and particle size.  
Not much information is available on the challenge of creating the drug/fatty acid ionic 
complex, but a simple drug-in-a-matrix approach would be less complex and would 
possibly allow for a broader range of drugs to be incorporated in the platform. 
 The KinetiSol® Dispersing (KSD) technology is a thermal process than can create 
solid amorphous systems from challenging drugs and very highly viscous polymers [71].  
While most publications on this technology deal with amorphous systems, the process can 
produce dispersions of crystalline drug just as straightforward as amorphous ones.  
Polymers with viscosity too large for process via extrusion have been successfully 
processed with KSD with the resulting solid systems being very difficult to mill once 
cooled [132].  While there is more to abuse deterrent systems than being difficult to mill, 
the viscous polymers do inherently provide resistance to crushing and powder formation.  
Additionally, the flexibility of KSD for polymer selection will allow for formulating with 
polymers that have inherent ethanol resistance like using polyvinyl alcohol (PVAL).  It is 
hypothesized that through KSD, very viscous polymers like high molecular weight 
hydroxypropylmethylcellulose (HPMC) can be combined with other excipients to create 
abuse deterrent formulations.  Furthermore, if combined with excipients that retard drug 
release, very viscous polymers can be formed into a multiparticulate extended release 
delivery form, providing dosing benefit to patients with dysphagia while not needing the 
complex processing of DETERx. 
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4.2 MATERIALS 
 Theophylline (THEO) was purchased from Acros Organics (Thermo Fisher 
Scientific).  HPMC grades were received from Dow Chemical Company or purchased from 
Ashland Chemical Company.  Ethocel (EC) grades were also sourced from Dow Chemical 
Company.   TEC and DBS was purchased from Vertellus.  EVAC and PVAL grades were 
purchased from Sigma-Aldrich. 
4.3 METHODS 
4.3.1 KinetiSol® Dispersing (KSD) 
Compositions for this study were produced by a lab scale, GMP pharmaceutical 
compounder designed and manufactured by DisperSol Technologies, L.L.C. (Georgetown, 
TX, USA).  Prior to KSD processing, materials were weighed, dispensed into a 
polyethylene bag, manually blended for approximately 1 minute, and charged into the 
compounder chamber.  For compositions with liquid components, the non-liquid 
components were weighed and placed into a food processor.  The liquid components were 
then weighed out in syringes that had been tared after being flushed with the liquid 
component (to compensate for the weight of residual liquid in the syringe after injection).  
The liquid was slowly added to the non-liquid components and then mixed on low setting 
for 2 minutes.  During processing in the compounder, computer controls monitor 
processing parameters in real time and eject the material at a pre-set ejection temperature.  
Discharged material was immediately quenched in a cooling die under pressure in a 
pneumatic press.  Cooled material was then milled in a FitzMill L1A with a 0.156 inch 
(approximately 5 mesh) screen after which particles smaller than a 12 mesh screen size 
were removed from the resulting material.  Formulations with high impact resistance 
required cooling with liquid nitrogen prior to milling. 
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4.3.2 Non-Sink Dissolution Analysis 
Non-sink dissolution analysis was conducted with a VK 7000 dissolution tester 
(Varian, Inc., Palo Alto, CA, USA) configured as Apparatus 2. Samples equivalent to 37.5 
mg THEO were weighed and added to the surface dissolution vessels filled with 750 ml of 
0.1 N HCl equilibrated to a temperature of 37.0 ± 1 °C with a paddle rotation of 50 rpm.  
Drug content in solution was directly measured at 270 nm with a fiber optic Spectra™ 
instrument (Pion Inc., Billerica, MA, USA) fitted with 5 mm path length Pion Probes.  
Readings were recorded every 10 minutes for 24 hours.  For dissolution containing ethanol, 
300 ml of ethanol was added to 450 ml of 0.1 N HCl and equilibrated to a temperature of 
37.0 ± 1 °C prior to adding samples. 
4.3.3 Dart Impact Test 
 Dart impact tests were conducted on a custom made testing device.  Essentially, a 
dart (solid steel cylinder) weighing 1.198 kg is placed with in PVC tube that is mounted 
vertically.  A string and pulley system allows the dart to be raised to a specific height and 
then released.  At the base of the PVC tube is a flat steel plate where a tablet is placed to 
be hit by the falling dart.  The dart is raised to 213 cm in height so that the tablet is hit with 
25 J of energy.  A tablet passed the test if it remained intact in one piece without visual 
cracks. 
4.3.4 Coffee Grinder Size Reduction Test 
 Approximately one gram of the multiparticulates is weighed out and placed in a 
KitchenAid coffee grinder.  The coffee grinder is turned on for 15 seconds followed by a 
15 second pause.  This is repeated for a total time of 5 minutes.  The ground material is 
then placed on top of a screen stack containing 20, 40, 60, and 200 mesh with a pan at the 
bottom to collect all fines that would pass through the 200 mesh.  The screen stack was 
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mechanically shaken for two minutes.  Each screen was weighted prior to sieving and then 
weighted afterward to determine the total weight of material in each size range. 
4.3.5 Syringeability Test 
 Approximately 500 mg of the multiparticulates were placed on a metal pan and held 
over a propane torch set on the lowest setting.  The height from the pan to the flame was 
slowly reduced until the heat was sufficient to start melting the particle surfaces.  Once 
molten, the pan could be tipped so the melted material could pool on the lip of the pan and 
be drawn up by a 20 gauge needle.  The needle and syringe were pre-weighed so that any 
material drawn up by the needled could be quantified by weighing the needle, syringe and 
drawn material. 
4.3.6 Water Extraction Test 
 Three 150 ml beakers were filled with 100 ml of distilled water and placed in three 
different conditions.  The first beaker was left at room temperature, the second one was 
placed on a hot plate and brought to a mild boil, and the last one was placed in an ice water 
bath to reach approximately 3 °C.  Once the three beakers achieved the desired conditions, 
25 mg of multiparticulate were placed in the water.  Drug content in solution was directly 
measured at 270 nm with a fiber optic Spectra™ instrument (Pion Inc., Billerica, MA, 
USA) fitted with 5 mm path length Pion Probes.  Readings were recorded every 2 minutes 
for 3 hours.  Test was concluded as soon as the water in the heated beaker reached a level 
that would not allow for complete submersion of the fiber optic tip.  The final volume was 
measured and concentrations were calculated on the average of the beginning and final 
volumes. 
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4.4 RESULTS AND DISCUSSION 
4.4.1 Formulation Development 
 In the previous chapters and in other research [132] where amorphous solid 
dispersions were created using high molecular weight polymers, it was discovered that 
milling the KSD discharged material was a challenge.  It was also discovered if the drug 
was not rendered amorphous, then the discharged material was significantly easier to mill.  
In general, it is known that drugs can function as plasticizers once they are rendered 
amorphous or molten and it has been found that ITZ works well as a plasticizer in cellulosic 
polymers [184].  Since drugs that are abused typically do not need bioavailability 
enhancement, it would be preferred to make solid dispersion with drugs in their unaltered 
or crystalline state.  However, not only would the composition not gain the benefit of the 
drug acting like a plasticizer, but the small, crystalline molecules would also have a 
negative impact on mechanical properties of the polymer. 
 To compensate for this, a small component of the formulation must have some 
plasticizing effect to retain impact properties sufficient to resist crushing or milling.  A 
screening study was conducted with 15 different excipients with HPMC E50 and 20% 
THEO by processing the compositions by KSD and then directly forming a tablet for dart 
impact testing.  For confidentiality reasons, the 15 excipients will not be listed in this 
chapter.  Six of the formulations successfully passed the impact test; two of them were 
selected to move forward with formulation development: triethyl citrate (TEC) and dibutyl 
sebacate (DBS).  TEC was selected because of the elastomeric properties that it imparted 
on HPMC, which makes it particularly impact resistant.  DBS was selected because it is 
less water soluble than TEC and might provide a slower release in dissolution testing. 
 The desired release rate from an extended release delivery form is drug and therapy 
dependent.  In this study, THEO is being used as a surrogate for an opioid like oxycodone 
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because of its high melting point and water/alcohol solubility.  For pain therapy, opioids 
have been tested for in 4-6 hour and 12 hour release [185].  For a starting point, the authors 
thought that a release profile around 6 hours could be representative of a target product 
profile and was selected as the development goal.  Several formulations were made from 
the selected group of materials, HPMC, EC, PVAL, EVAC, TEC and DBS, and tested in 
dissolution.  Formulations that required at least 3 hours to achieve full drug in solution are 
listed in Table 4.2.  Along with the time to achieve full release, the table also contains an 
impact rating, which was a subjective categorization after manually bending the discharged 
after cooling in the compression mold.  A rating of 1 was very easy to break, a rating of 2 
required some effort to break, and a rating of 3 was very difficult or impossible to break. 
 
Formulation Time to full 
release 
Impact 
rating 
62% HPMC E50 / 10% HPMC K100M / 8% TEC 3:00 3 
44% PVAL 4-38 / 36% K100M 3:10 2 
40% PVAL 4-88 / 40% PVAL 4-98 3:20 1 
40% EVAC 12 / 30% HPMC K100M / 10% EC 10 4:00 1 
40% EVAC 12 / 40% HPMC K100M 4:10 2 
52% HPMC E50 / 10% EC 10 / 10% HPMC K100M / 8% TEC 4:10 2 
42% HPMC E50 / 20% EC 10 / 10% HPMC K100M / 8% TEC 4:30 1 
30% HPMC E15 / 30% HPMC K100M / 20% DBS  5:40 3 
35% HPMC E15 / 35% HPMC K100M / 10% DBS 6:40 3 
55% EC 10 / 25% DBS 35% in 24:00 1 
80% EVAC 12 20% in 24:00 3 
Table 4.2: Formulations tested to determine excipient trends (n=1). 
 Many of the formulations initially tested attained full release in around 2 hours, so 
the formulation focus turned to determining combinations that released THEO very slowly.  
EVAC is used for extended release transdermal drug delivery [186] and is used in the 
plastic industry as an impact modifier [187]; consequently, it was not surprising that it 
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required more than 24 hours to release and received an impact rating of 3.  EVAC was 
introduced into formulations containing HPMC E50 and it did slow the release.  But, the 
time to full release was still faster than three hours and the impact rating of the 
compositions were 2 or less.   When combined with HPMC K100M, a release time of 4 
hours was achieved but again the impact rating was 2 or less.  Ethyl Cellulose is used in 
formulations for extended release and lends itself well to thermal processing [188].  Mixed 
with a high percentage of DBS yielded a composition that required more than 24 hours to 
release.  However, EC is brittle and very easy to grind or mill.  It was added at 10 and 20% 
in several formulations and generally aided in slow down release.  Unfortunately, the 
negative impact on the mechanical properties even at 10% was sufficient to make all 
formulations a rating of 2 or less even with the impact augmenting effects of TEC.   
 HPMC K100M in combination with both plasticizers proved to be the best 
mechanical property enhancing approach in formulation development, but most of the 
release times were between 3 and 4 hours.  Other HPMC grades were added to the 
formulations both to make the composition easier to process and to alter the release profile.  
Eventually, a combination of E15, K100M and DBS generated a release profile around 6 
hours and earned an impact rating of 3. 
 As mentioned in the introduction section, one of the common methods for abuse is 
to consume alcohol simultaneously with the dosage form to defeat the extended release 
feature and attain dose dumping.  Thus, the last step of the formulation process was to see 
the release profile in 40% ethanol compared with the release in 0.1 N HCl to determine if 
further formulation adjustments were needed.  Figure 4.1 contains the dissolution profiles 
of the two conditions for the lead formulation of 20% THEO / 35% HPMC E15 / 35% 
HPMC K100M / 10% DBS. 
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Figure 4.1: Dissolution profiles of lead formulation in 0.1 N HCl and 40% Ethanol 
(n=3). 
 The lead formulation actually had a slightly slower dissolution rate in the media 
containing 40% ethanol than it did the standard media.  An F2 similarity factor was 
calculated to compare the two dissolution profiles and a value of 90 was obtained [189].  
This indicated that there is less than 2% variance between the two profiles.  Thus, the lead 
formulation meets to the main performance criteria of releasing the drug over 6 hours, 
having good mechanical properties for impact resistance, and having a release profile that 
is not significantly altered by ethanol. 
4.4.2 Abuse Testing 
 A reduction in particle size will cause an increase in the dissolution rate.  Thus, one 
of the abuse methods is to reduce the delivery form to a fine powder to have an immediate 
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release rate.  The multiparticulates produced in this study are in the size range of 1.7 to 4 
mm.  All the particles that were smaller than a 12 mesh screen were removed from the 
multiparticulates, so the smallest size corresponds with the 12 mesh screen which is 1.7 
mm.  The 4 mm size on the large end of the spectrum corresponds with the milling screen 
size.  The coffee grinder size reduction test was conducted on the lead formulation with the 
results of the mass fraction analysis shown in Figure 4.2. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Post Coffee Grinder Test Particle Size distribution. 
 The small sieve stack was limited in sizes, so the percentage of particles larger than 
12 mesh could not be measured.  However, almost 62% of the multiparticulates were over 
the 20 mesh size which shows that very little size reduction did occur on the majority of 
the particles.  None of the particles were reduced in size to a fine powder (less than 75 
microns) which is a positive result to keep the delivery form from being rendered an 
immediate release.  The remaining particles were scattered in sizes ranging from 75 to 850 
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microns.  The real indication of the effect of the coffee grinder size reduction test is to 
perform a dissolution comparison which is illustrated in Figure 4.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Dissolution Profile of Original Size and Coffee Ground Material (n=3). 
 As expected, the ground material had a faster dissolution rate than the original size 
material, but it was not an immediate release profile.  The T95 (time where 95% of the 
drug has been released) and T80 (time for 80%) was 4:42 and 2:32 for the original size and 
3:32 and 1:42 for the coffee ground material, which is approximately a time reduction of 
30%.   An F2 similarity factor was calculated for the entire profile and for the first three 
hours with values of 84 and 67 respectively, which is a difference of roughly 5%.  While 
it is a change in the dissolution performance, the ground material still retained an extended 
release profile to serve as an abuse deterrent. 
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 Skeptics of this test might argue that the coffee grinder was only run intermittently 
for 5 minutes and if it were processed consistently for a longer duration of time that the 
particle size reduction would allow for immediate release.  Prior to having access to a 
Fitzmill in early KSD research studies, coffee grinders were used for size reduction of the 
discharge of amorphous dispersions.  Several coffee grinders were broken until a method 
was discovered to grind high molecular weight polymers without causing damage to the 
grinder.  If the coffee grinders were run continuously, the surfaces of the particles are 
heated up by the friction occurring in the grinder.  As the surface temperatures of the 
particles rises, they become soft and tacky.  The tacky surfaces create a much higher 
resistance to rotation, which will result in breaking the drive shaft or burning out the electric 
motor.  It is likely that an individual attempting to abuse the delivery form for the first time 
would not take such precautions and cause damage to the coffee grinder, which would 
probably motivate the person to change to a different method of tampering. 
 A mortar and pestle was employed to see if size reduction could be achieved.  
Figure 4.4 is a picture of the material after test to show that no particle size reduction or 
powder was formed. 
 
 
 
 
 
 
 
Figure 4.4: Mortar and Pestle approach for size reduction of multiparticulates. 
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 After 5 minutes of vigorously attempting size reduction in the mortar and pestle, no 
size reduction was observed.  A hammer test was briefly attempted, where the 
multiparticulates were placed in a polyethylene bag and hit with a hammer.  The first 
impact did substantial damage to the plastic bag and the second impact caused some 
multiparticulates to fly across the room.  No size reduction was observed and the test was 
ceased for safety reasons.  With the results from the coffee grinder, mortar and pestle, and 
hammer testing, it was concluded that the lead formulation did provide good resistance to 
size reduction. 
 The syringeability test was then conducted on the lead formulation as illustrated in 
Figure 4.5. 
 
 
 
 
 
 
 
 
 
Figure 4.5: Result of Syringeability test of lead formulation. 
 As the particles were heated up, the surfaces in contact with the pan would melt 
and then instantly char.  Some of the particles in the figure demonstrate this as the bottom 
is black while the top is still unmelted.  It is possible that the heat transfer rate is too high 
from the propane torch and causing the surface to burn before the top portion of the particle 
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received enough heat to melt.  Consequently, the test was conducted on a hot plate where 
the temperature was slowly raised over approximately 15 minutes to allow time for 
sufficient heat transfer.  Even with the slower heat transfer rate, the particles burned on the 
bottom and remained solid on the top (picture not shown).  Thus, this action was not a 
result of the method of heating, but rather the performance of the formulation. 
 As the bottom of the particles started to melt/char, the pan was tilted to get the 
material to flow the lip of the pan for possible collection in the needle.  Interestingly, the 
particles would move, but the portion that melted on the bottom would not flow.  The 
particle would slowly disintegrate as it slid along the pan, which would leave a trail, but 
would stop moving once the particle completely melted.  A trail can be seen in the picture 
on the left hand side.  The right hand side of the picture shows the portion of particles 
completely melted together.  After the particles on the right were melted, the pan was 
slopped so that the material would flow to the right; however, the material would not pour.  
As the pan was removed from the heat source, the liquefied portions became hard within a 
few seconds.  Because of the behavior of the material, none of it was able to be drawn 
through the needle into the syringe.  It was concluded that abuse by this method is not 
practical. 
 The final step for testing abuse deterrence in this study was the water extraction 
test.  The results are shown in Figure 4.6. 
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Figure 4.6: Dissolution Profiles from the Water Extraction Test. 
 The delivery form did release slowly in ice water and room temperature water; at 
the 1:15 time point there was 5% and 13% released respectively.  However, the boiling 
water allowed for around 40% of the drug to be released in the first 15 minutes.  
Intriguingly, the multiparticulates in the boiling water appeared to have little or no physical 
change as they were similar in hardness and color at the end of the test.  The 
multiparticulates placed in the room temperature and ice water baths had increased in size 
due to water absorption, turned white in color and had taken a gelatin consistency.  It seems 
hydration of the formulation is key in retarding drug release and that hot water prevents 
water absorption.  This finding is consistent with product literature on HPMC [190, 191]. 
 It is beyond the scope of this study to reformulate in an attempt to address the hot 
water release issue.  Possibly, using a lower grade of HPMC, like E3, along with a different 
plasticizer or combination of plasticizers would allow for the composition to hydrate in 
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boiling water while retaining the mechanical properties of the lead formulation.  Effort on 
achieving a more narrow range of particle sizes would provide a more uniform release rate 
and varying the average particle size could modify the time to full drug release.  Many 
aspects could be investigated and optimized to improve this basic concept.  However, the 
study has shown that high molecular weight polymers, especially HPMC, can be 
formulated for mechanical resistance to abuse methods and provide extended drug release.  
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4.5 CONCLUSION 
 Abuse of prescription medication is a large social challenge facing the United States 
today.  Abuse deterrent formulations have been introduced into the market and have shown 
to discourage abusers from using those medicaments nonmedically.  Some patient 
populations struggle with swallowing those formulations and would benefit from a 
multiparticulate abuse delivery form.  This study has shown that high molecular weight 
polymers, primarily HPMC, can be combined with plasticizers to create a delivery form 
that is resistant to size reduction by coffee grinder, mortar and pestle and hammering.  The 
same formulation shows ethanol will not cause dose dumping and also resistance to 
syringeability.  While good water extraction resistance was established, it could be 
improved upon to resist extraction in hot water.  Further research could allow this concept 
to be developed commercially and aid in the fight against the epidemic of prescription drug 
overdose deaths. 
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